World Journal of *Gastrointestinal Oncology*

World J Gastrointest Oncol 2021 November 15; 13(11): 1544-1849





Published by Baishideng Publishing Group Inc

WU

Generation World Journal of Gastrointestinal Oncology

Contents

Monthly Volume 13 Number 11 November 15, 2021

EDITORIAL

1544 Inhibition of poly (ADP-Ribose) polymerase: A promising strategy targeting pancreatic cancer with **BRCAness** phenotype

Jeong KY, Lee H

OPINION REVIEW

New drugs for the treatment of metastatic colorectal cancer 1551 Cherri S, Libertini M, Zaniboni A

REVIEW

1561 Extracellular vesicles: General features and usefulness in diagnosis and therapeutic management of colorectal cancer

Mammes A, Pasquier J, Mammes O, Conti M, Douard R, Loric S

1599 Radiomics in hepatocellular carcinoma: A state-of-the-art review Yao S, Ye Z, Wei Y, Jiang HY, Song B

1616 Gut microbiota and immune system in liver cancer: Promising therapeutic implication from development to treatment

Bartolini I, Risaliti M, Tucci R, Muiesan P, Ringressi MN, Taddei A, Amedei A

- 1632 Role of mammalian target of rapamycin complex 2 in primary and secondary liver cancer Joechle K, Guenzle J, Hellerbrand C, Strnad P, Cramer T, Neumann UP, Lang SA
- 1648 Regulatory role of the transforming growth factor- β signaling pathway in the drug resistance of gastrointestinal cancers

Lv X, Xu G

MINIREVIEWS

- 1668 Novel perspective in pancreatic cancer therapy: Targeting ferroptosis pathway Yang Y, Zhang ZJ, Wen Y, Xiong L, Huang YP, Wang YX, Liu K
- 1680 Liver tumors in children with chronic liver diseases Sintusek P, Phewplung T, Sanpavat A, Poovorawan Y

1696 Non-surgical treatment of hilar cholangiocarcinoma

Inchingolo R, Acquafredda F, Ferraro V, Laera L, Surico G, Surgo A, Fiorentino A, Marini S, de'Angelis N, Memeo R, Spiliopoulos S



Monthly Volume 13 Number 11 November 15, 2021

ORIGINAL ARTICLE

Basic Study

1709 Genome-wide CRISPR-Cas9 screening identifies that hypoxia-inducible factor-1a-induced CBX8 transcription promotes pancreatic cancer progression via IRS1/AKT axis

Teng BW, Zhang KD, Yang YH, Guo ZY, Chen WW, Qiu ZJ

- Shuyu pills inhibit immune escape and enhance chemosensitization in hepatocellular carcinoma 1725 Deng Z, Teng YJ, Zhou Q, Ouyang ZG, Hu YX, Long HP, Hu MJ, Mei S, Lin FX, Dai XJ, Zhang BY, Feng T, Tian XF
- 1741 Preventive and inhibitive effects of Yiwei Xiaoyu granules on the development and progression of spasmolytic polypeptide-expressing metaplasia lesions

Chen WQ, Tian FL, Zhang JW, Yang XJ, Li YP

1755 Effects of dietary zinc deficiency on esophageal squamous cell proliferation and the mechanisms involved Chen Y, Liu FX, Liu H

Case Control Study

1766 Genetic variation of TGF-BR2 as a protective genotype for the development of colorectal cancer in men Stanilov N, Grigorova A, Velikova T, Stanilova SA

Clinical Trials Study

1781 Induction chemotherapy with albumin-bound paclitaxel plus lobaplatin followed by concurrent radiochemotherapy for locally advanced esophageal cancer

Yan MH, Liu F, Qu BL, Cai BN, Yu W, Dai XK

SYSTEMATIC REVIEWS

1791 Colorectal cancer in Arab world: A systematic review

> Makhlouf NA, Abdel-Gawad M, Mahros AM, Lashen SA, Zaghloul M, Eliwa A, Elshemy EE, Ali-Eldin Z, Abdeltawab D, El-Raey F, Omran D, Khalaf M, Fanous N, Abdelmohsen AS, Abu-Elfatth A, Abdelghani M, Fanouk M, Abdelaziz M, Alboraie М

1799 Cell-free DNA liquid biopsy for early detection of gastrointestinal cancers: A systematic review

Uhe I, Hagen ME, Ris F, Meyer J, Toso C, Douissard J

1813 Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review

Ahmed F, Onwumeh-Okwundu J, Yukselen Z, Endaya Coronel MK, Zaidi M, Guntipalli P, Garimella V, Gudapati S, Mezidor MD, Andrews K, Mouchli M, Shahini E

META-ANALYSIS

Anatomical vs nonanatomical liver resection for solitary hepatocellular carcinoma: A systematic review 1833 and meta-analysis

Liu H, Hu FJ, Li H, Lan T, Wu H



Contents

World Journal of Gastrointestinal Oncology

Monthly Volume 13 Number 11 November 15, 2021

LETTER TO THE EDITOR

1847 Hepatocellular carcinoma biomarkers, an imminent need Zamora-León SP



World Journal of Gastrointestinal Oncology

Contents

Monthly Volume 13 Number 11 November 15, 2021

ABOUT COVER

Editorial Board Member of World Journal of Gastrointestinal Oncology, Wen-Wei Sung, MD, PhD, Associate Professor, Doctor, Surgeon, Department of Urology; School of Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan, Taichung 40201, Taiwan. flutewayne@gmail.com

AIMS AND SCOPE

The primary aim of World Journal of Gastrointestinal Oncology (WJGO, World J Gastrointest Oncol) is to provide scholars and readers from various fields of gastrointestinal oncology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJGO mainly publishes articles reporting research results and findings obtained in the field of gastrointestinal oncology and covering a wide range of topics including liver cell adenoma, gastric neoplasms, appendiceal neoplasms, biliary tract neoplasms, hepatocellular carcinoma, pancreatic carcinoma, cecal neoplasms, colonic neoplasms, colorectal neoplasms, duodenal neoplasms, esophageal neoplasms, gallbladder neoplasms, etc.

INDEXING/ABSTRACTING

The WJGO is now indexed in Science Citation Index Expanded (also known as SciSearch®), PubMed, PubMed Central, and Scopus. The 2021 edition of Journal Citation Reports® cites the 2020 impact factor (IF) for WJGO as 3.393; IF without journal self cites: 3.333; 5-year IF: 3.519; Journal Citation Indicator: 0.5; Ranking: 163 among 242 journals in oncology; Quartile category: Q3; Ranking: 60 among 92 journals in gastroenterology and hepatology; and Quartile category: Q3. The WJGO's CiteScore for 2020 is 3.3 and Scopus CiteScore rank 2020: Gastroenterology is 70/136.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Ying-Yi Yuan; Production Department Director: Xiang Li; Editorial Office Director: Ya-Juan Ma.

NAME OF JOURNAL World Journal of Gastrointestinal Oncology	INSTRUCTIONS TO AUTHORS https://www.wjgnet.com/bpg/gerinfo/204
ISSN ISSN 1948-5204 (online)	GUIDELINES FOR ETHICS DOCUMENTS https://www.wjgnet.com/bpg/GerInfo/287
LAUNCH DATE	GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
February 15, 2009	https://www.wjgnet.com/bpg/gerinfo/240
FREQUENCY	PUBLICATION ETHICS
Monthly	https://www.wjgnet.com/bpg/GerInfo/288
EDITORS-IN-CHIEF	PUBLICATION MISCONDUCT
Rosa M Jimenez Rodriguez, Pashtoon M Kasi, Monjur Ahmed, Florin Burada	https://www.wjgnet.com/bpg/gerinfo/208
EDITORIAL BOARD MEMBERS	ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/1948-5204/editorialboard.htm	https://www.wjgnet.com/bpg/gerinfo/242
PUBLICATION DATE	STEPS FOR SUBMITTING MANUSCRIPTS
November 15, 2021	https://www.wjgnet.com/bpg/GerInfo/239
COPYRIGHT	ONLINE SUBMISSION
© 2021 Baishideng Publishing Group Inc	https://www.f6publishing.com

© 2021 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA E-mail: bpgoffice@wjgnet.com https://www.wjgnet.com



0 WÛ

World Journal of **Gastrointestinal** Oncology

Submit a Manuscript: https://www.f6publishing.com

World J Gastrointest Oncol 2021 November 15; 13(11): 1813-1832

DOI: 10.4251/wjgo.v13.i11.1813

ISSN 1948-5204 (online)

SYSTEMATIC REVIEWS

Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review

Faiza Ahmed, Jennifer Onwumeh-Okwundu, Zeynep Yukselen, Maria-Kassandra Endaya Coronel, Madiha Zaidi, Prathima Guntipalli, Vamsi Garimella, Sravya Gudapati, Marc Darlene Mezidor, Kim Andrews, Mohamad Mouchli, Endrit Shahini

ORCID number: Faiza Ahmed 0000-0002-6751-5178: Jennifer Onwumeh-Okwundu 0000-0002-7457-3544; Zeynep Yukselen 0000-0002-4875-6355; Maria-Kassandra Endaya Coronel 0000-0002-0288-2129; Madiha Zaidi 0000-0001-5775-8945; Prathima Guntipalli 0000-0002-6683-9357; Vamsi Garimella 0000-0003-4743-7456; Sravya Gudapati 0000-0003-4557-0288; Marc Darlene Mezidor 0000-0002-6446-5101: Kim Andrews 0000-0002-0304-9630; Mohamad Mouchli 0000-0002-5343-2427; Endrit Shahini 0000-0002-4909-0436.

Author contributions: Ahmed F, Onwumeh-Okwundu J, and Shahini E were the guarantors of the study; Ahmed F and Onwumeh-Okwundu J contributed to the study conception, design, and data acquisition, and supervised the drafting of the manuscript; Ahmed F, Mouchli M, and Shahini E critically reviewed the manuscript; Ahmed F, Endaya Coronel MK, Mouchli M, and Shahini E assisted in formatting, editing and revising the manuscript; All authors interpreted the data, participated in drafting the manuscript, critically revised the article for important intellectual content, and

Faiza Ahmed, Zeynep Yukselen, Maria-Kassandra Endaya Coronel, Madiha Zaidi, Prathima Guntipalli, Division of Clinical and Translational Research, Larkin Community Hospital, South Miami, FL 33143, United States

Jennifer Onwumeh-Okwundu, Community Health Division, University of Stellenbosch, Stellenbosch 7602, South Africa

Vamsi Garimella, College of Medicine, Howard University, Washington, DC 520, United States

Sravya Gudapati, College of Medicine, Washington University of Health and Science, San Pedro, Belize

Marc Darlene Mezidor, Department of Radiology, Amita Health Saint Francis Hospital, Evaston, IL 60202, United States

Kim Andrews, Department of Mathematics and Natural Sciences, Prince Mohammad Bin Fahad University, Al Khobar 31952, Saudi Arabia

Mohamad Mouchli, Department of Gastroenterology, Cleveland Clinic, Cleveland, OH 44195, United States

Endrit Shahini, National Institute of Gastroenterology "S. de Bellis", Research Hospital, Castellana Grotte (Bari) 70013, Italy

Corresponding author: Endrit Shahini, MD, MSc, National Institute of Gastroenterology "S. de Bellis", Research Hospital, Castellana Grotte (Bari), Via Turi 27, Castellana Grotte (Bari) 70013, Italy. endrit.shahini@irccsdebellis.it

Abstract

BACKGROUND

Despite the use of current standard therapy, the prognosis of patients with unresectable hepatocellular carcinoma (HCC) is poor, with median survival times of 40 mo for intermediate HCC (Barcelona Clinic Liver Cancer [BCLC] stage B) and 6-8 mo for advanced HCC (BCLC stage C). Although patients with earlystage HCC are usually suitable for therapies with curative intention, up to 70% of



gave final approval of the article to be published.

Conflict-of-interest statement: The authors declare no conflict of interests for this article.

PRISMA 2009 Checklist statement:

The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: htt p://creativecommons.org/License s/by-nc/4.0/

Provenance and peer review:

Invited article; Externally peer reviewed.

Specialty type: Oncology

Country/Territory of origin: Italy

Peer-review report's scientific quality classification

Grade A (Excellent): 0 Grade B (Very good): 0 Grade C (Good): C, C Grade D (Fair): 0 Grade E (Poor): 0

Received: March 12, 2021 Peer-review started: March 12, 2021 First decision: May 3, 2021 Revised: May 11, 2021 Accepted: August 25, 2021 Article in press: August 25, 2021 Published online: November 15, 2021

P-Reviewer: Akarsu M, Katada K S-Editor: Fan JR L-Editor: Filipodia P-Editor: Li JH

patients experience relapse within 5 years. In the past decade, the United States Food and Drug Administration has approved different immunogenic treatment options for advanced HCC, the most common type of liver cancer among adults. Nevertheless, no treatment is useful in the adjuvant setting. Since 2007, the multikinase inhibitor sorafenib has been used as a first-line targeted drug to address the increased mortality and incidence rates of HCC. However, in 2020, the IMbrave150 trial demonstrated that combination therapy of atezolizumab (antiprogrammed death-ligand 1 [PD-L1]) and bevacizumab (anti-vascular endothelial growth factor [VEGF]) is superior to sorafenib, a single anti-programmed death 1/PD-L1 antibody inhibitor used as an anti-cancer monotherapy for HCC treatment.

AIM

To conduct a systematic literature review to evaluate the evidence supporting the efficacy and safety of atezolizumab/bevacizumab as preferred first-line drug therapy over the conventional sorafenib or atezolizumab monotherapies, which are used to improve survival outcomes and reduce disease progression in patients with unresectable HCC and non-decompensated liver disease.

METHODS

A comprehensive literature review was conducted using the PubMed, Scopus, ScienceDirect, clinicaltrials.gov, PubMed Central, Embase, EuropePMC, and CINAHL databases to identify studies that met the inclusion criteria using relevant MeSH terms. This systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and risk of bias (RoB) were assessed using the Cochrane RoB 2 tool and Sevis.

RESULTS

In the atezolizumab/bevacizumab group, an improvement in overall tumor response, reduction of disease progression, and longer progression-free survival were observed compared to monotherapy with either sorafenib or atezolizumab. Hypertension and proteinuria were the most common adverse events, and the rates of adverse events were comparable to those with the monotherapy. Of the studies, there were two completed trials and two ongoing trials analyzed using high quality and low bias. A more thorough analysis was only performed on the completed trials.

CONCLUSION

Treatment of HCC with atezolizumab/bevacizumab combination therapy was confirmed to be an effective first-line treatment to improve survival in patients with unresectable HCC and non-decompensated liver disease compared to monotherapy with either sorafenib or atezolizumab.

Key Words: Hepatic malignancy; Combination systemic therapy; Immunogenetic therapy; Liver transplantation; Barcelona clinic liver cancer; Transarterial chemoembolization

©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Hepatocellular carcinoma (HCC), the most common primary malignancy of the liver, is a leading cause of cancer-related deaths. Combination immunotherapy for the treatment of advanced HCC is attracting increasing attention because of the superiority of clinical results compared to sorafenib, the standard of care. Combination therapy with atezolizumab/bevacizumab has been compared to sorafenib and atezolizumab monotherapies. Current findings indicate that combination therapy is as effective as first-line therapeutic options for improving survival rates in patients with unresectable HCC and non-decompensated liver disease.

Citation: Ahmed F, Onwumeh-Okwundu J, Yukselen Z, Endaya Coronel MK, Zaidi M, Guntipalli P, Garimella V, Gudapati S, Mezidor MD, Andrews K, Mouchli M, Shahini E. Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable





hepatocellular carcinoma: A systematic review. World J Gastrointest Oncol 2021; 13(11): 1813-1832

URL: https://www.wjgnet.com/1948-5204/full/v13/i11/1813.htm DOI: https://dx.doi.org/10.4251/wjgo.v13.i11.1813

INTRODUCTION

Hepatocellular carcinoma (HCC) accounts for 75%-85% of primary liver cancers, and is the sixth most common cancer and fourth leading cause of cancer-related deaths worldwide[1]. Surgical resection, thermal ablation, and liver transplantation represent the conventional approaches used for patients with early-stage HCC (Barcelona Clinic Liver Cancer [BCLC] stage A). Moreover, for patients who are not surgical candidates, systemic chemotherapy can be alternatively employed. Patients with early-stage HCC are usually suitable for curative treatments. However, the prognosis of patients with unresectable HCC is usually poor, with median survival times of 40 mo for intermediate HCC (BCLC stage B) and 6-8 mo for advanced HCC (BCLC stage C)[2]. Moreover, up to 70% of patients experience disease recurrence within 5 years, with no beneficial effects in the adjuvant setting[3].

Tumor cells can activate different immune checkpoint pathways that modify immunosuppressive functions. Specifically, in the last several decades, the emergence of immune checkpoint inhibitors (ICIs) that target the human programmed deathligand 1 (PD-L1)/programmed death 1 (PD-1) pathway has led to the high potential to treat a wide spectrum of solid tumors including HCC[4].

Sorafenib (BAY 43-9006) is a multi-kinase inhibitor that blocks the activity of Raf serine/threonine kinase, as well as other receptor tyrosine kinases such as VEGFR-2 and VEGFR-3, platelet-derived growth factor receptor- β , c-KIT, fms-like tyrosine kinase 3, and RET. Its ability to block these pathways leads to the inhibition of tumor angiogenesis, tumor cell proliferation, and migration while increasing the rate of apoptosis[5,6].

In 2007, the United States Food and Drug Administration (FDA) approved sorafenib for the treatment of metastatic HCC due to its anti-angiogenic properties[6]. It has shown survival benefits by extending the median survival time of patients with unresectable HCC (10.7 mo compared to 7.9 mo in the placebo group)[2].

Atezolizumab, another ICI of interest, is a monoclonal antibody that targets PD-L1 [7] and prevents the interaction between the PD-1 and A7-1 receptors, resulting in the reversal of T-cell suppression[8]. Bevacizumab is an anti-angiogenic antibody that inhibits angiogenesis and neoplasm growth by targeting VEGF[9]. Anti-VEGF treatments can decrease VEGF-mediated immunosuppression and also improve anti-PD-1/PD-L1 functions[10,11].

Given the nature of these immunotherapies, it has been postulated that a combination of atezolizumab with bevacizumab should have safe and synergistic antitumor effects on HCC. The phase III IMbrave150 trial showed that bevacizumab combined with atezolizumab leads to better overall survival (OS) and progression-free survival (PFS) outcomes over sorafenib therapy in patients with unresectable HCC [12]. Moreover, atezolizumab/bevacizumab combination therapy was also demonstrated to be the first regimen to improve patients' quality of life, significantly delaying the median time to deterioration compared to sorafenib[12]. Given the better performance of atezolizumab/bevacizumab, FDA approved the combination drug therapy for patients with advanced HCC as first-line therapy on May 29, 2020[13].

The synergistic effects of atezolizumab-bevacizumab therapy compared to the sorafenib monotherapy are remarkable enough to warrant further study. Hence, this systematic review analyzed the documented evidence comparing the efficacy and safety of atezolizumab/bevacizumab combination therapy with monotherapy regimens, such as sorafenib or atezolizumab, in patients with unresectable HCC (Supplementary Figure 1).

MATERIALS AND METHODS

Criteria for considering studies

This study included a data collection of randomized controlled trials (RCTs), which evaluated adult patients (aged 18 and older) with unresectable HCC to receive



combination therapy of intravenous atezolizumab (1200 mg) plus bevacizumab (15 mg/kg) every 3 wk (or periodically). The study dataset was further divided into a control segment consisting of sorafenib monotherapy, atezolizumab monotherapy, or placebo.

The RCTs incorporated primary efficacy outcomes of mortality, measured as a median number of deaths and stratified hazard ratios (HRs). Moreover, the Response Evaluation Criteria in Solid Tumors (RECIST) criteria (Supplementary Table 1) measured secondary outcomes of OS, median OS, and median PFS as tumor response proportions or percentages. An example of the aforementioned was demonstrated in the overall confirmed objective response, confirmed complete and partial responses, stable disease, progressive disease, and disease control rate.

RCTs safety measurements evaluated included patients with adverse events (AEs) from causes that included serious treatment-related AEs and treatment-related mortality events. Additionally, AEs that resulted from drug dosing modifications and/or interruptions were evaluated along with drug withdrawal trials that included participants with Grade 3-5 AEs. Any unfavorable clinical or laboratory result associated with an investigational intervention during the clinical trial was considered an AE; hence, this included any unfavorable and life-threatening medical outcome that required inpatient hospitalization or prolongation of hospitalization.

All RCTs evaluated in the study had documented hepatitis virological status as well as a Child-Pugh classification of A or B (Supplementary Table 2). However, the data excluded trials involving patients who received treatments for medical conditions other than HCC, as well as participants with autoimmune liver disease or any autoimmune conditions and participants in Child-Pugh class C. Non-human studies, non-English and unpublished articles were also excluded.

Search methods for the identification of studies

A comprehensive and extensive literature review of published articles was conducted to identify RCTs that met the inclusion and exclusion criteria using appropriate MeSH terms. This systematic review was performed following the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses. The search was conducted using the Cochrane, Cochrane Central, PubMed Central, Scopus, Science-Direct, WHO trials, clinicaltrials.gov, Google Scholar, Embase, CINAHL, and MedLine databases. The following terms and Boolean operators were employed in MeSH and free-text searches to identify relevant articles: "Hepatocellular carcinoma," "liver tumor," "liver cancer," "atezolizumab and bevacizumab," and "sorafenib."

The data search was conducted until December 27, 2020. The search criteria were broadened by identifying additional studies from the reference lists of selected articles, as well as by the "related articles" function of PubMed. Additionally, the systematic review was registered in PROSPERO, the international prospective registry of systematic reviews of the National Institute for Health Research (CRD42021237736). For transparency, the study was pre-registered on the open science framework (URL: https://osf.io/esvk9), and in PROSPERO.

Data collection and analysis

Selection of studies: All articles used in this document were screened for eligibility via their titles and abstracts. Thereafter, the full-text of all chosen studies was examined in detail. Two independent reviewers were chosen to perform the screening and examination process according to predefined eligibility criteria for the qualitative review.


Data extraction and management


Two review authors (MKC and MZ) independently extracted the data and summarized the trial characteristics in each table. They were also involved in extracting the baseline characteristics of the participants, study design, geography, settings, methods, types of interventions (dosage, route of administration, regimen protocol), efficacy, and safety outcomes.

Assessment of risk of bias in included studies

This study assessed the risk of bias (RoB) in the included studies by using the revised Cochrane RoB 2 tool for randomized trials. This tool was used to assess the RoB across the following five domains: Bias arising from the randomization process, bias due to deviation from the intended intervention, bias due to missing outcome, bias in the measurement of outcome, and bias in the selection of the reported results. Moreover, the Robvis data software was used to create a RoB traffic light plot (Figure 1) and a







RoB summary plot (Figure 2).

Protocol for missing data

The studies that measured relevant objective data outcomes (e.g., mean survival rates) according to their study protocols, but included non-retrievable online data, missing content or unclear data, were cleared up by reaching out to the original authors of the published reports. However, if no response was obtained from the original authors, the selected study was excluded from the analyses.

Data synthesis

A descriptive analysis of all study results was performed. All continuous variables such as mean and median were analyzed, and all dichotomous outcomes were investigated as proportions and percentages. Furthermore, epidemiological variables (e.g., risk ratio, attributable risk, and numbers needed to treat) to measure certain effects of intervention such as mortality were estimated as deemed necessary.

RESULTS

The results of the literature search are summarized in Figure 3. Initially, 520 potentially eligible articles were considered. However, 326 full-text articles that were predominantly cohort studies and a few RCTs were evaluated after screening the abstracts. Subsequently, four RCTs were included in the literature search after excluding 516 articles according to the eligibility criteria. Of the four trials included, two were ongoing (La Roche^[14] and Hack et al^[15]), and two have been concluded (Finn et al[12], 2020, and Lee et al[16], 2020). Data from the ongoing clinical trials and completed studies are illustrated in Table 1. Hence, the two completed trials were included in the final analyses.

Study design and setting of included studies

This review included the two concluded trials in the present analyses (Finn *et al*[12] and Lee *et al*[16]) as well as the results of two currently ongoing trials of La Roche[14]and Hack *et al*^[15] that will be used in future updates.

La Roche^[14] is a Phase IIIb, single-component, multicenter study of atezolizumab/bevacizumab, which is currently ongoing. Hack *et al*[15] is also currently ongoing, and is evaluating randomized patients included in an intervention dataset (atezolizumab/bevacizumab) and patients assigned to the control portion of the dataset undergoing active surveillance. Patients included in the control were allowed to crossover to the intervention dataset (atezolizumab/bevacizumab) after confirmed recurrence

Lee *et al*[16] is part of an open-label, multicenter, multi-segmental, phase 1b study also known as GO30140 study, which enrolled patients at 26 academic centers and community oncology practices in seven countries worldwide. The study included five cohorts, but only the results of the two HCC cohorts, Groups A (atezolizumab monotherapy) and F, are described within this review article. Finn et al[12] compared the intervention dataset (atezolizumab/bevacizumab) with the control dataset (sorafenib monotherapy) and compared patients from 111 sites in 17 countries. Hence, details of the trials and participants are shown in Table 1.

As La Roche[14] and Hack et al[15] are currently ongoing, information for primary and secondary objectives are incomplete. It should be noted that while incomplete



Table 1 Characteristics of the two ongoing and two completed clinical trials

Contry of enrollanest Ialay 70 sites in 25 countries (Asia) Shudy design Single carm, multi- Centra, randomized clinical control mill Multi-centre randomized clinical control mill Shudy quaity NA (study is-sill ungning) NA (study is-sill ungning) Shudy quaity NA (study is-sill ungning) NA (study is-sill ungning) Intervention Does at accilization by 100 mercery 3 wk + breaccontron 15 mg/ kg/ VQW Does at accilization by 100 mercery 3 wk + breaccontron 15 mg/ kg/ VQW Control Study and of care breast provide control arm reported Does at accilization by 100 mercery 3 wk + breaccontron 15 mg/ kg/ VQW Nataber of patients 530 662 Intervention/control Intervention Ant specified Intervention 501 Intervention/control Not reported Not reported Intervention/control Not reported Median progression-free survival Median progression-free survival Median progression-free survival Recet control Does proved survival Yes of outcomes reported Median progression-free survival Median progression-free survival Median progression-free survival Control forsio Doratin or response	Ongoing clinical trials	La Roche[14], 2020	Hack <i>et al</i> [<mark>15</mark>], 2020
indindindShaypalonNoNoShaypalonNoNoShaypalonNoNoShaypalonAkabizanab plas beaciamabNoInterentionBandard plas beaciamabDece assolaranab 120 mg every 3 wk 1 beaciaranab 130 mg every 3 wk 1 	Country of enrollment	Italy	170 sites in 25 countries (Asia)
Number of patientsNA (study is still engoing)NA (study is still engoing)InterventionAccolizamab plob bevacizamabAccolizamab plob BevacizamabControlBandard of careActive surveillanceNo rescritizations for control arm reportedAccolizamab plob BevacizamabNamer of patientsBioAccolizamabIntervention/controlIntervention end specifiedAccolizamabMarkan of patientsBioAccolizamabActive specifiedControlAccolizamabMarkan of patientsNo reportedAccolizamabActive specifiedSocial SpecifiedAccolizamabMarkan of patientsNo reportedControlActive specifiedNo reportedSocial SpecifiedActive specifiedNo reportedControlParation of follow-up in moNo reportedControlTypes of outcomes reportedActive specifiedControlActive specifiedControlControlActive specifiedControlControlActive specifiedAccilization for specifiedGordal SpecifiedActive specifiedControlControlActive specifiedControlSpecifiedActive specifiedAccolization specifiedControlActive specifiedControlControlActive specifiedAccolization specifiedControlActive specifiedControlControlActive specifiedControlControlActive specifiedControlControlActive specified<	Study design		
InterventionAccolumab plus besericatumabAccolumab plus besericatumabInterventionBandard of careActive anveilianceb 120 mg very 3 vk.*ControlBandard of careActive anveilianceb 120 mg very 3 vk.*Nonsecrifications for control arm reportedEvencinumb 120 mg very 3 vk.*Number of putients15062Intervention/controlIntervention of specifiedControl. 119Active any enditionNot reportedStady included individuals > 18 yrAdvisor of follow-up in moStudy included individuals > 18 yrStudy included individuals > 18 yrOrardion of follow-up in moNot reportedControl. 66 moIntervention/controlControl. 56 moControl. 65 moDeration of follow-up in moNot reportedControl. 65 moIntervention/controlControl. 55 adverse eventsControl. 65 moIntervention/controlCondel 55 adverse eventsCondel 5 adverse eventsIntervention/controlDiscose controlDiscose controlDiscose controlDiscose controlDiscose controlDiscose controlNo forsporseinSolita progression survivalCompleted studiesNo forsporsein survivalSolita progression fore survivalStudy do	Study phase	ШЬ	III
DescriptionDescriptionDescriptionDescriptionDescriptionControlStandard of careActive survailanceNomber of patients150Active survailanceNumber of patients150Active survailanceMarkan of patients150Active survailanceMarkan age (range)Intervention onto specifiedNote portedMarkan age (range)Note portedStady included individuals >18 yrAustion of follow-up in moNote portedStady included individuals >18 yrAustron of follow-up in moNote portedStady included individuals >18 yrDypes of outcomes reportedOverall survivalControl: 6.5 moAustro of sollow app in moNote portedStady included individuals >18 yrAustro of sollow app in moNote portedStady included individuals >18 yrDypes of outcomes reportedOverall survivalStady included individuals >18 yrAustro of sollow app in moNote portedStady included individuals >18 yrAustro of sollow app in moNote portedStady included individuals >18 yrAustro of sollow app in moNote portedStady included individuals >18 yrAustro of sollow app in moNote portedStady included individuals >18 yrAustro of sollow app in moNote portedStady included individuals >18 yrAustro of sollow app in moNote portedStady included individuals >18 yrAustro of sollow app in moNote portedStady included individuals >18 yrAustro of sollow app in moNote portedStad	Study quality	NA (study is still ongoing)	NA (study is still ongoing)
Intervention Bewaizumab IS mg/kg IV Q3W Bewaizumab IS mg/kerey 3 wk Control Nalveor of patients Notes serverillance Number of patients IJO 642 Intervention/control Intervention not specified Intervention SU Control: Not specified Control: 119 Median age (ongo) Not reported Staty included individuals > 18 yr Oursel of follow-up in mo Not peorted Control: So mo Purset of follow-up in mo Not peorted Control: So mo Intervention/control Control: So mo Control: So mo Types of outcomes reported Overall survival Median progression-free survival Intervention/control Control: So mo So motore Types of outcomes reported Overall survival Median progression-free survival Intervention/control Control: So mo So motore Disease control Disease control Disease control Intervention of response Disease control So motore Completed studies No (study is still engoing) So sites in 7 countries, which include the Uninted sites: Chan, Jpan, South Korea, Tawan, Austerial	Intervention	Atezolizumab plus bevacizumab	Atezolizumab plus bevacizumab
Number of patientsisoperification encoded and expectingNumber of patients1062Intervention (centralIntervention expectifiedIntervention expectifiedNumber of patientNot portedCentral: 19Maran of patientStatis patient expectifiedIntervention expectifiedIntervention (centralStatis patient expectifiedIntervention expectifiedIntervention (centralVersion expectifiedIntervention expectified<			
Number of patients9062Intercention/controlIntercention to specifiedIntercention 50Median age (range)Not reportedControl: 19Median age (range)Not reportedStudy included individuals > 18 yr1-bration of follow up in moNot reportedIntercention?1-bration of follow up in moNot reportedControl: 15 mol1-bration of follow up in moNot reportedIntercention?1-bration of follow up in moNot reportedControl: 8.6 mo1-bration of follow up in moNot reportedControl: 8.6 mo1-bration of follow up in moNot reportedControl: 8.6 mo1-bration of follow up in moOverall survivalMedian progression-free survival1-bration of follow up in moNot reportedControl: 8.6 mo1-bration of response reportedGrade 3.5 adverse eventsGrade 3.6 adverse events1-bration of response rateDisease controlDisease control1-bration of responseForm of R[12] 2020Lee af [16], 20201-bration of segonseStates, China, Japan, Cernange, Surdh Sore, Japan, South Sore, Jaman, Australia, and States, China, Japan, Cernange, France, Surdh Sore, Japan, South Sore, Jaman, Australia, and States, China, Japan, Cernange, France, Surdh Sore, Japan, South Sore, Jaman, Australia, and Sore, China, Japan, Cernange, France, South Sore, Jaman, Australia, and Sore, China, Japan, Cernange, France, South Sore, Jaman, Australia, and Sore, China, Japan, Cernange, France, South Sore, Jaman, Australia, and Sore, China, Japan, Cernange, France, South Sore, Jaman, Australia, and Sore, China, Japan, Cernange, South Sore, Jaman, Australia, and Sore	Control	Standard of care	Active surveillance
Intervention (ontrol pecifiedIntervention 30Intervention (ontrol PeriodKote portedMedian age (ange)Kote portedIntervention (ontrolStudy included individuals > 18 yrIntervention (ontrolKote portedIntervention (ontrolKote portedIntervention (ontrolControl : 65 moIntervention (ontrolControl : 65 moIntervention (ontrolControl : 65 moIntervention (ontrol : 65 moControl : 65 mo <td></td> <td>No specifications for control arm reported</td> <td></td>		No specifications for control arm reported	
InterventionControl. Not specifiedControl. 19Median age (range)Not reportedNot reportedIntervention/controlStudy included individuals > 18 yrStudy included individuals > 18 yrDuration of follow-up in moNot reportedIntervention: 8.6 moIntervention/controlControl: 6.5 moControl: 6.5 moTypes of outcomes reportedNoreall survivalMedian progression-free survivalMedian progression-free survivalMedian progression-free survivalGrade 3 of 4 adverse eventsMedian progression-free survivalGrade 3 of a daverse eventsGrade 3 of 4 adverse eventsMedian progression-free survivalDisease controlGrade 3 of a daverse eventsMine to progressionTime to progressionTime to progressionMunition of resporseTime to progressionTime to progressionMunition of resporseStuding still ongoing)Studing still ongoing)Completed studiesNo (study i still ongoing)Studing still ongoing)Comply is of EnrollmentStuding Transence, South Kroen, Studing studing contention, Such Krienched the United Studies, Chana, Japan, Cermany, France, South Kroen, Studing and Studing adverse free in this studyFloreIIStuding adverse free in this studyFloreIIStuding adverse free in this studyFloreIIStuding adverse free in this studyStudy designQuert adverse design adverse free in this studyFloreIIStuding adverse design adverse event in the studyFloreIIStuding adverse event in this study	Number of patients	150	662
Median age (range)Not reportedNot reportedIntervention/controlNot reportedIntervention: 8.6 moIntervention/controlControl: 8.6 moIntervention/controlControl: 6.5 moIntervention/controlNo (study is still ongoing)Intervention/controlSolies in Jocontries, which include the United Solies. Jopan, South Koroe, Taiwan, Australia, and New Solies. Jopan,	Intervention/control	Intervention not specified	Intervention 501
Intervention/controlStudy included individuals > 18 yrDuration of follow-up in moNot reportedIntervention: 86 moIntervention/controlControl: 65 moTypes of outcomes reportedOverall survivalOverall survivalMedian progression-free survivalMedian progression-free survivalGrade 3 or 4 adverse eventsGrade 3-5 adverse eventsGrade 3 or 4 adverse eventsGrade 3 or 4 adverse eventsDisease controlObjective response rateDisease controlDuration of responseDuration of response-Post-progressionNA (study is still ongoing)NA (study is still ongoing)Study is still ongoing)Interventines, which include the United Status, parso, Compatibility, Study and Adverse, Chima, Japan, Scudy, Study and Scudy and FareStudy designOpen-label, randomized clinical trialStatus, parso, South Korea, Taiwan, Australia, and Status, parso, South Korea, Taiwan, Australia, and<		Control: Not specified	Control: 119
Duration of follow-up in moNot reportedIntervention: 8.6 moIntervention/controlControl: 6.5 moTypes of outcomes reportedOverall survivalOverall survivalMedian progression-free survivalMedian progression-free survivalGrade 3 or 4 adverse eventsDisease controlDisease controlDisease controlObjective response rateTime to progressionTime to progressionData that could not be evaluated/dataNA (study is still ongoing)NA (study is still ongoing)Country/ise of EnrollmentFinn et al[12], 2020Lee et al[16], 2020Country/ise of EnrollmentStates, China, Japan, Germany, France, South Korea, Taiwan, Australia, and New ZealandStudy designUp enable, randomized clinical trialMulti-arm study with five cohortsPhaseIIILow risk of biasLow risk of biasPhaseIIIDoe: 1200 mg atezolizumab + 15 mg/kg of bevarizumab [Ng with yq withDoe: 1200 mg atezolizumab + 15 mg/kg of bevarizumab Ng with yq with qwControlSourie (100 mg sorafenib PO BID)Doe: 120 mg atezolizumab + 15 mg/kg of bevarizumab Ng with yq with qw	Median age (range)	Not reported	Not reported
Intervention/controlControl: 6.5 moTypes of outcomes reportedOverall survivalMedian progression-free survivalMedian progression-free survivalMedian progression-free survivalGrade 3.5 adverse eventsDisease controlDisease controlDisease controlDisease controlOrigetive response rateTime to progressionData that could not be evaluated/dataNa (study is still ongoing)Nath to could not be evaluated/dataFin ar al[2],2020Completed studiesFin ar al[2],2020Country/ies of EnrollmentJissis in 37 countries, which include the United States, Linus, Japan, Germany, France, South Korea, Russia, Canada, and TaiwanStudy designOpen-label, randomized clinical trialPhaseIIStudy designLow risk of biasPhaseIIStudy QualityLow risk of biasInterventionAccolizumab Pilos PoracizumabPhaseIIStudy CaulityAccolizumab Pilos PoracizumabInterventionCorrige and controlersprogresPhaseIIStudy CaulityLow risk of biasControlAccolizumab Pilos PoracizumabStudy CaulityLow risk of biasControlDes: 1200 mg atezolizumab + 15 mg/kg of bevarizumab IV q3wStudy GaulityStudy monotherapyAction of poraciene PO BDIDes: 1200 mg atezolizumabAutored Filos PO BDIDes: 1200 mg atezolizumabAutored Filos PO BDIDes: 1200 mg atezolizumabAutored Filos PO BDIDes: 1200 mg atez	Intervention/control	Study included individuals > 18 yr	Study included individuals > 18 yr
Types of outcomes reportedOverall survivalOverall survivalMedian progression-free survivalMedian progression-free survivalGrade 3-5 adverse eventsGrade 3 or 4 adverse eventsDisease controlDisease controlObjective response rateDisease controlDarato for oprogressionDisease controlDarato for oprogression survivalDisease controlOraphogene dataNa (study is still ongoing)Oraphogene dataSalese, China Japan, Cermany, France, South Korea, Japan, South Korea, Taiwan, Australia, and Sales, Sales, China Japan, Cermany, France, South Korea, Japan, South Korea, Taiwan, Australia, and Sales, China Japan, Cermany, France, South Korea, Japan, South Korea, Taiwan, Australia, and Sales, China Japan, Cermany, France, South Korea, Japan, South Korea, Taiwan, Australia, and Sales, China Japan, Cermany, France, South Korea, Japan, South Korea, Taiwan, Australia, and Sales, China Japan, Cermany, France, South Korea, Japan, South Korea, Taiwan, Australia, and Sales, China Japan, Cermany, France, South Korea, Japan, South Korea, Taiwan, Australia, and New ZealandStudy designOpen-Jaele, randomized clinical trialMulti-arm study utif five cohortsPhaseIIIster study with five cohorts facus in on a face data face dat	-Duration of follow-up in mo	Not reported	Intervention: 8.6 mo
AMedian progression-free survivalMedian progression-free survivalGrade 3-5 adverse eventsGrade 3 or 4 adverse eventsDisease controlDisease controlObjective response rateTime to progressionDuration of responseToest-progression survivalData that could not be evaluated/dataNA (study is still ongoing)Data that could not be evaluated/dataFinn et al[12], 2020Completed studiesFinn et al[12], 2020Country/ies of EnrollmentJ11 sites in 17 countries, which include the United States, Cinina, Japan Germany, France, South Korea, States, Japan, South Korea, Taiwan, Australia, and New ZealandStudy designOpen-label, randomized clinical trialMulti-arm study with five cohortsPhaseIIIIusHowever, only the two cohorts focusing on hepacellular carcinoma, Groups A and FivanPhaseIIILow risk of biasLow risk of biasControlDose: 1200 mg atezolizumab + 15 mg/kg of bevacizumab IV q3wDose: 1200 mg atezolizumab + 15 mg/kg of bevacizumab IV q3wControlSouries 1200 mg atezolizumab + 15 mg/kg of bevacizumab IV q3wDose: 1200 mg atezolizumab + 15 mg/kg of bevacizumab IV q3wControlSouries 400 mg sorafentib PO BIDDose: 1200 mg atezolizumabDose: 1200 mg atezolizumabNumber of patientsSouries 400 mg sorafentib PO BIDDose: 1200 mg atezolizumabDose: 1200 mg atezolizumab	Intervention/control		Control: 6.5 mo
Image: ControlGrade 3 of a daverse eventsGrade 3 of a daverse eventsDisease controlDisease controlDisease controlObjective response rateTime to progressionTime to progressionDuration of responseDuration of responseTotal of responseData that could not be evaluated/dataNA (study is still ongoing)NA (study is still ongoing)Data that could not be evaluated/dataStates In 2 outries which include the UnitedStates in 7 outries which include the UnitedGrande 3 states, China, Japan, Germany, France, South Korea, Taiwan, Australia, and States, China, Japan, Germany, France, South Korea, Taiwan, Australia, and States, Japan, South Korea, States, Japan, South Korea, States, Japan, South Korea, St	Types of outcomes reported	Overall survival	Overall survival
Index outputDisease controlDisease controlOperative response rateTime to progressionDuration of responseTotalion of responseDuration of responseTotalion of responsePost-progression survivalTotalion of responseCompleted studiesNa (study is still ongoing)Comprised studiesFine of 2020Country/ies of EnrollmentStates China, Japan, Germany, France, South Korea, Taiwan, Australia, and Suess, Canada, and TaiwanStudy designOpen-label, randomized clinical trialPhaseIIPadey QualityIowisk of biasInterventionMexistor Japan, South Sorea, Taiwan, Australia, and Suess, Diapan, South Korea, Taiwan, Aust		Median progression-free survival	Median progression-free survival
Image: Problem Series		Grade 3-5 adverse events	Grade 3 or 4 adverse events
Image of the progressionDuration of responseDuration of responsePost-progression survivalData that could not be evaluated/dataNA (study is still ongoing)Completed studiesCompleted studiesFinn et al[12], 2020Country/ies of EnrollmentStudy lesignOpen-label, randomized clinical trialMulti-arm study with five cohorts Russia, Canada, and TaiwanStudy designOpen-label, randomized clinical trialPhaseIIIStudy QualityLever is of biasInterventionAtezolizumab F15 mg/kg of bevarizumab IV q3wOcntrolSorafenib monotherapy bevarizumab IV q3wAtezolizumab IV q3wKumber of patientsStudy on gargenib POBIDNumber of patientsStudy of patientsSorafenib POBIDStudy of patientsStudy of patientsStudy QualityStudy Quali		Disease control	Disease control
Duration of responsePost-progression survivalPost-progression survivalPata that could not be evaluated/data missingNA (study is still ongoing)NA (study is still ongoing)Completed studiesFinn et al[12, 2020Lee et al[16], 2020Country/ies of EnrollmentSites, China, Japan, Cermany, France, South Korea, Russia, Canada, and TaiwanSites in 7 countries, which include the United States, China, Japan, Cermany, France, South Korea, Russia, Canada, and TaiwanMulti-arm study with five cohortsStudy designOpen-label, randomized clinical trialMulti-arm study with five cohortsPhaseIILow risk of biasLow risk of biasStudy QualityLow risk of biasLow risk of biasInterventionAteolizumab plus bevacizumabMuterus plus bevacizumabPhaseIIDose: 1200 ng atezolizumab + 15 mg/kg of bevacizumab IV q3wControlCorrigon gategolizumab + 15 mg/kg of bevacizumab IV q3wDose: 1200 ng atezolizumab + 15 mg/kg of bevacizumab IV q3wControlSore et align bonotherapy France, Bono gategolizumab + 15 mg/kg of bevacizumab IV q3wDose: 1200 ng atezolizumab + 15 mg/kg of bevacizumab IV q3wControlSore et align bonotherapy France, Bono gategolizumab + 15 mg/kg of bevacizumab IV q3wDose: 1200 ng atezolizumab + 15 mg/kg of bevacizumab IV q3wControlSore et align bonotherapy France, Bono gategolizumab + 15 mg/kg of bevacizumab IV q3wDose: 1200 ng atezolizumab + 15 mg/kg of bevacizumab IV q3wControlSore et align bonotherapy France, Bono gategolizumab + 15 mg/kg of bevacizumab IV q3		Objective response rate	
Post-progression survivalData tat could not be evaluated/dai missingN4 (study is still ongoing)N4 (study is still ongoing)Completed studiesFine <i>et al</i> [12, 2020Lee <i>et al</i> [16], 2020Country/ies of EnrollmentJistes in 17 countries, which include the United States, Ichnia, Japan, Germany, France, South Kore Russia, Canada, and TaiwanSoites in 7 countries, which include the United States, Japan, South Korea, Taiwan, Australia, and New ZealandStudy designOpen-label, randomized clinical trialMulti-arm study with five cohorts Australia, and F, are described here in this studyPhaseIIIbStudy QualityLow risk of biasLow risk of biasInterventionAtezolizumab plus bevacizumabMezolizumab plus bevacizumabAuzon Low risk of biasIbSetter Low risk of biasControlOrafenib monotherapy bevacizumab F15 mg/kg of bevacizumab		Time to progression	
Data that could not be evaluated/data missingNA (study is still ongoing)NA (study is still ongoing)Completed studiesFinn et al[12], 2020Lee et al[16], 2020Country/ies of Enrollment111 sites in 17 countries, which include the United States, China, Japan, Germany, France, South Korea, Russia, Canada, and Taiwan26 sites in 7 countries, which include the United States, Japan, South Korea, Taiwan, Australia, and New ZealandStudy designOpen-label, randomized clinical trialMulti-arm study with five cohorts However, only the two cohorts focusing on hepatocellular carcinoma, Groups A and F, are described here in this studyPhaseIIIIbStudy QualityLow risk of biasLow risk of biasInterventionAtezolizumab plus bevacizumabAtezolizumab plus bevacizumab bevacizumab IV q3wControlSorafenib monotherapy Dose: 1200 mg atezolizumab + 15 mg/kg of bevacizumab IV q3wDose: 1200 mg atezolizumab + 15 mg/kg of bevacizumab IV q3wKunber of patientsSol 400 mg sorafenib PO BIDDose: 1200 mg atezolizumab		Duration of response	
missingLevel of the construction of the c		Post-progression survival	
Country/ies of Enrollment111 site of the function of the second states, china, Japan, Germany, France, South Korea, Russia, Canada, and Taiwan26 sites in 7 countries, which include the United States, Japan, South Korea, Taiwan, Australia, and New ZealandStudy designOpen-label, randomized clinical trialMulti-arm study with five cohortsStudy designOpen-label, randomized clinical trialMulti-arm study with five cohortsPhaseIIIIbStudy QualityLow risk of biasLow risk of biasInterventionAtezolizumab plus bevacizumabAtezolizumab plus bevacizumabDose: 1200 mg atezolizumab 15 mg/kg of bevacizumab IV q3wDose: 1200 mg atezolizumab + 15 mg/kg of bevacizumab IV q3wControlSorafenib monotherapy Dose: 400 mg sorafenib PO BIDDose: 1200 mg atezolizumabNumber of patientsSol1403		NA (study is still ongoing)	NA (study is still ongoing)
States, China, Japan, Germany, France, South Korea, Russia, Canada, and TaiwanStates, Japan, South Korea, Taiwan, Australia, and New ZealandStudy designOpen-label, randomized clinical trialMulti-arm study with five cohorts However, only the two cohorts focusing on hepatocellular carcinoma, Groups A and F, are described here in this studyPhaseIIIIbStudy QualityLow risk of biasLow risk of biasInterventionAtezolizumab plus bevacizumab bevacizumab IV q3wAtezolizumab + 15 mg/kg of bevacizumab IV q3wControlSorafenib monotherapy Dose: 1200 mg atezolizumabDose: 1200 mg atezolizumabNumber of patientsSol1403	Completed studies	Finn <i>et al</i> [12] , 2020	Lee <i>et al</i> [16], 2020
PhaseIIIHowever, only the two cohorts focusing on hepatocellular carcinoma, Groups A and F, are described here in this studyPhaseIIIIbStudy QualityLow risk of biasLow risk of biasInterventionAtezolizumab plus bevacizumabAtezolizumab plus bevacizumabDose: 1200 mg atezolizumab + 15 mg/kg of bevacizumab IV q3wDose: 1200 mg atezolizumab + 15 mg/kg of bevacizumab IV q3wControlSorafenib monotherapy Dose: 400 mg sorafenib PO BIDAtezolizumab i atezolizumabNumber of patientsSol403	Country/ies of Enrollment	States, China, Japan, Germany, France, South Korea,	States, Japan, South Korea, Taiwan, Australia, and
PhaseIIIbe described here in this studyStudy QualityLow risk of biasLow risk of biasInterventionAtezolizumab plus bevacizumabAtezolizumab plus bevacizumabDose: 1200 mg atezolizumab + 15 mg/kg of bevacizumab IV q3wDose: 1200 mg atezolizumab + 15 mg/kg of bevacizumab IV q3wControlSorafenib monotherapy Dose: 400 mg sorafenib PO BIDAtezolizumab monotherapy Dose: 1200 mg atezolizumabNumber of patientsSol403	Study design	Open-label, randomized clinical trial	Multi-arm study with five cohorts
Study QualityLow risk of biasLow risk of biasInterventionAteolizumab plus bevacizumabAteolizumab plus bevacizumabDose: 1200 mg ateolizumab + 15 mg/kg of bevacizumab IV q3wDose: 1200 mg ateolizumab + 15 mg/kg of bevacizumab IV q3wControlSorafenib monotherapy bese 400 mg sorafenib PO BIDAteolizumab monotherapy bese 1200 mg ateolizumabNumber of patientsSolMonotherapySolMonotherapyMonotherapySolM			hepatocellular carcinoma, Groups A and F, are
InterventionAtezolizumab plus bevacizumabAtezolizumab plus bevacizumabInterventionAtezolizumab plus bevacizumabDose: 1200 mg atezolizumabDose: 1200 mg atezolizumab + 15 mg/kg of bevacizumab IV q3wDose: 1200 mg atezolizumab + 15 mg/kg of bevacizumab IV q3wControlSorafenib monotherapy Dose: 400 mg sorafenib PO BIDAtezolizumab monotherapy Dose: 1200 mg atezolizumabNumber of patientsSol403	Phase	III	Ib
Number of patients Final Properties	Study Quality	Low risk of bias	Low risk of bias
bevacizumab IV q3wbevacizumab IV q3wControlSorafenib monotherapy Dose: 400 mg sorafenib PO BIDAtezolizumab monotherapy Dose: 1200 mg atezolizumabNumber of patients501403	Intervention	Atezolizumab plus bevacizumab	Atezolizumab plus bevacizumab
Number of patients 501 Dose: 100			
Number of patients501403	Control	Sorafenib monotherapy	Atezolizumab monotherapy
		Dose: 400 mg sorafenib PO BID	Dose: 1200 mg atezolizumab
Intervention/control Intervention: 336 Group A ¹ : 104	Number of patients	501	403
	Intervention/control	Intervention: 336	Group A ¹ : 104

Baisbideng® WJGO | https://www.wjgnet.com

	0 + 14/5	
	Control: 165	Group F+: 60
		Control:
		59 included in efficacy analysis ¹
		58 included in safety analysis
		1 discontinued before receiving any treatment due to elevated alkaline phosphatase concentrations ¹
Median duration of follow-up (mo, [IQR])	Overall: 8.6 mo	Overall follow-up not given, see stratified data below
Intervention/control		Group A ¹ : 12.4 (IQR 8.0-16.2)
	Intervention: 8.9	Group F+: 6.6 (IQR 5.5-8.5)
		Control: 6.7 (IQR 4.2-8.2)
	Control: 8.1	
Primary outcomes reported	Mortality rates	Mortality rates
	Hazard ratio for death	Hazard ratio for death
Secondary Outcomes reported	Overall survival	Overall survival
	Median progression free survival	Median progression free survival
	Grade 3-5 adverse events	Grade 3-4 adverse events
	Disease control	Disease control
	Objective response rate	Objective response rate
	Time to progression	Time to progression
	Duration of response	Duration of response
	Post-progression survival	Post-progression survival

¹Group A: Patients with hepatitis B virus DNA of 500 IU/mL or less and ongoing anti-hepatitis B virus treatment for at least 3 mo before and at study entry; patients enrolled in Group F must have had hepatitis B virus DNA of 500 IU/mL or less measured up to 28 d before study entry and anti-hepatitis B virus treatment for at least 14 d before study entry. +: Group F: Patients in Child-Pugh class A, life expectancy of 3 mo and platelet count or > 75000/µL. NA: Not applicable.




Figure 2 Summary plot of the risk of bias assessment of the two completed studies.

data were not assessed in this document, the authors of this manuscript fully intend to obtain updated data concerning related objectives in the future.

The Finn *et al*[12] and Lee *et al*[16] studies encompass a total of 724 patients and have been evaluated as follows. All clinical trials comprised a large sample of patients recruited from more than 310 sites across more than 20 countries. The countries included sites in North America (United States, Canada), Europe (United Kingdom, Germany, France, Italy, Poland, Spain, Russia, Czech Republic), and Asia-Pacific (China mainland, Japan, Republic of Korea, Taiwan, Australia, Hong Kong, Russia, Singapore, and New Zealand). The distribution of sites is shown in Figure 4. The specific patient profiles of La Roche[14] and Hack *et al*[15] have not yet been published (Table 1).

Ahmed F et al. Efficacy and safety of atezolizumab with bevacizumab




Figure 3 Preferred reporting items for systematic reviews and meta-analyses diagram.




Figure 4 Distribution of study sites.

Participants

The clinical trials recruited adult volunteers of both genders, with locally advanced metastatic or unresectable HCC (or both). All trials used the American Association for the Study of Liver Disease criteria for histologic, cytologic, and clinical diagnostic confirmation. A documented hepatitis virological status was also required and a history of autoimmune disease was considered an exclusion criterion.

Raishideng® WJGO | https://www.wjgnet.com

Eligible patients in the trials, who had not previously received systemic therapy for HCC, had an Eastern Cooperative Oncology Group (ECOG) performance score of either 0 or 1 and a Child-Pugh class of A or B (Supplementary Table 2). The studies attributed their exclusion of Child-Pugh class C to the increased risk of patient death due to related underlying cirrhosis. The patients with underlying cirrhosis were excluded from the study to avoid potentially confounding impact on the assessment of treatment-related antitumor efficacy. La Roche[14], Finn *et al*[12], and Lee *et al*[16] included patients who had HCC that was measurable as *per* the RECIST 1.1 (Supplementary Table 1). However, there was no specific mention of RECIST 1.1 in Hack *et al*[15].

Moreover, Hack *et al*[15], Finn *et al*[12], and Lee *et al*[16] employed BCLC staging (Supplementary Table 3). There was no specific mention of BCLC staging in La Roche [14].

Baseline characteristics of patients across the two completed trials and treatment modalities were adequately balanced (Table 2). Both studies had a median age range of about 63-years-old. Specifically, Finn *et al*[12] had a median age of 64 (interquartile range, [IQR], 56-71) and 66 (IQR, 59-71) years for its interventional (atezolizumab/bevacizumab) and control (sorafenib monotherapy), respectively. Whereas Lee *et al*[16] had a median age of 62 (IQR, 23-82) for Group A (atezolizumab/bevacizumab), 60 (IQR, 22-82) for Group F (atezolizumab/bevacizumab) and 63 (23-85) for the control (atezolizumab monotherapy), respectively. Both studies predominantly included the male sex (83%), Asian (62%) and Caucasian (30%) ethnicities, Child-Pugh class A (99%), and advanced BCLC (stage C) (84%) in the treatment and control groups. Both studies reported a higher prevalence of patients with extrahepatic spread, positivity for hepatitis B, and a history of alcohol use. Finn et al[12] included mostly ECOG 0 patients than ECOG 1, while the opposite was observed for Lee et al[16] Only about 35% of patients across the studies had alphafetoprotein > 400 ng *per* milliliter. Regarding PD-L1 status, more patients had tumor cell or immune cell \geq 1% than any other classification, across treatment and control for both studies. Finn *et al*[12] showed the number of patients who previously experienced local therapy for HCC, and almost half of the patients had at least one treatment on both the atezolizumab/bevacizumab (48%, 161/336 patients) and sorafenib (52%, 85/165 patients) arms. Whereas Lee et al[16] did not show those patients who had prior local therapy for HCC.

There were no significant differences that were explicitly stated between interventional and control in the published manuscripts of Finn *et al*[12] and Lee *et al*[16]. The following baseline characteristics were evaluated for differences: Median age, sex, race, geographic region, Child-Pugh class, ECOG stage, BCLC stage, alpha-fetoprotein levels, macrovascular invasion, extrahepatic spread, hepatitis status, alcohol use, PD-L1 status, and prior local therapy for HCC. Moreover, regarding gastroesophageal varices (current/treated), there were no specific indications of statistically significant differences between the interventional and control groups in Finn *et al*[12] as well. On the other hand, Lee *et al*[16] did not report the prevalence of varices but stated that varices were managed when present, according to the standard of care.

Primary outcomes

Mortality rates: According to Finn *et al*[12], mortality occurred in 28.6% of patients (96/336) in the atezolizumab/bevacizumab group during a follow-up duration of 8.9 mo at the clinical data cut-off, and was significantly lower than that reported in the sorafenib group (39.4%; 65/165 patients) during a similar surveillance time of 8.1 mo (P < 0.001 by χ^2) (Table 3).

The overall mortality reported by Lee *et al*[16] in the atezolizumab/bevacizumab group was significantly different (higher in Group A, 27% [16/104 patients] and zero in Group F, [0/60 patients]; P < 0.0001 by χ^2), and was significantly lower than that in the atezolizumab group (31%; 18/59 patients) at a median follow-up of 12.4 mo (P < 0.0001 by χ^2). Lee *et al*[16] also showed a 7% mortality (7/10 patients) in Group A and did not report deaths related to AEs in Group F.

Using epidemiological analyses, this review estimated the relative risk (RR) of death from the combination therapy *vs* the monotherapy to be 0.72 (Finn *et al*[12]) and 0.87 (Lee *et al*[16]), respectively. The calculated RR reduction was 0.28 and 0.13, respectively, for both studies. The attributable risk was 0.108 (Finn *et al*[12]) and 0.04 (Lee *et al*[16]), and the number needed to treat (NNT) 9.2 for atezolizumab/bevacizumab *vs* sorafenib (Finn *et al*[12]), whereas the NNT was 25 for atezolizumab/ bevacizumab *vs* atezolizumab alone (Lee *et al*[16]).

Zaishideng® WJGO | https://www.wjgnet.com

	Finn <i>et al</i> [<mark>12</mark>], 2020		Lee et al[<mark>16</mark>],	2020	
	Interventional arm	Control arm	Interventional	arm	Control arm
	Atezolizumab- bevacizumab combination therapy	Sorafenib monotherapy	Atezolizumab-bevacizumab combination therapy given in both Arms A and F		Atezolizumab monotherapy
			Group A	Group F+	_
	<i>n</i> = 336	<i>n</i> = 165	<i>n</i> = 104	<i>n</i> = 60	n = 59
Median age (IQR), yr	64 (56-71)	66 (59-71)	62 (23-82)	60 (22-82)	63 (23-85)
Gender, <i>n</i> (%)					
Male	277 (82)	137 (83)	84 (81)	54 (90)	49 (83)
Female	59 (18)	28 (17)	20 (19)	6 (10)	10 (17)
Race, n (%)					
White	123 (37)	52 (32)	20 (19)	14 (23)	9 (15)
Asian	188 (56)	96 (58)	75 (72)	45 (75)	47 (80)
Black or African American	6 (1.8)	4 (2.4)	7 (7)	1 (2)	2 (3)
Native Hawaiian or other Pacific Islander	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)
Unknown	19 (6)	12 (7)	2 (2)	0 (0)	0 (0)
Geographic region, n (%)					
Asian excluding Japan	133 (40)	68 (41)	59 (57)	39 (65)	39 (66)
Rest of the world (United States, Australia, New Zealand, and Japan)	203 (60)	97 (59)	45 (43)	21 (35)	20 (34)
Child Pugh, n (%)					
Child Pugh A5	239 (72)	121 (73)	77 (74)	43 (72)	42 (71)
Child Pugh A6	94 (28)	44 (27)	21 (20)	17 (28)	17 (29)
Child Pugh A7	0 (0)	0	6 (6)	17 (28)	17 (29)
Child Pugh B	1 (< 1)	0 (0)	NA	NA	NA
ECOG performance status, <i>n</i> (%)					
ECOG 0	209 (62)	103 (62)	52 (50)	27 (45)	25 (42)
ECOG 1	127 (38)	62 (38)	52 (50)	33 (55)	34 (58)
BCLC, n (%)					
BCLC stage A (early)	8 (2)	6 (4)	0 (0)	0 (0)	2 (3)
BCLC stage B (intermediate)	52 (15)	26 (16)	10 (10)	6 (10)	4 (7)
BCLC stage C (advanced)	276 (82)	133 (81)	94 (90)	54 (90)	53 (90)
Alpha-fetoprotein > 400 ng <i>per</i> milliliter	126 (38%)	61 (37%)	37 (36%)	18 (30%)	19 (32%)
Macrovascular invasion	129 (38%)	71 (43%)	55 (53%)	20 (33%)	25 (42%)
Extrahepatic spread	212 (63%)	93 (56%)	91 (88%)	47 (78%)	50 (85%)
Hepatitis B	164 (49%)	76 (46%)	51 (49%)	34 (57%)	32 (54%)
Hepatitis C	72 (21%)	36 (22%)	31 (30%)	11 (18%)	10 (17%)
Non-viral	100 (30%)	85 (52%)	22 (21%)	15 (25%)	17 (29%)
Alcohol use, n (%)					
Previous	166 (50)	79 (48)	58 (56)	39 (65)	32 (54)
Never	121 (36)	61 (37)	32 (31)	14 (23)	21 (36)



Current	48 (14)	25 (15)	14 (13)	7 (12)	6 (10)
Varices at baseline	88 (26%)	43 (26%)	NA	NA	NA
Varices treated at baseline	36 (11%)	23 (14%)	NA	NA	NA
PD-L1 status, <i>n</i> (%)	124	58	NA	NA	NA
TC and IC < 1%	45 (36)	25 (43)	25 (24)	15 (25)	18 (31)
TC or IC $\geq 1\%$	79 (64)	33 (57)	61 (59)	28 (47)	34 (58)
$TC \ge 5\%$ or $IC \ge 5\%$	46 (37)	17 (29)	37 (36)	8 (13)	16 (27)
TC \ge 10% or IC \ge 10%	12 (10)	5 (9)	30 (29)	5 (8)	6 (10)
Data missing	NA	NA	18 (17)	17 (28)	8 (14)
Prior local therapy for HCC, <i>n</i> (%)					
At least one treatment	161 (48)	85 (52)	NA	NA	NA
Transarterial chemoembolization	130 (39)	70 (42)	NA	NA	NA
Radiofrequency ablation	47 (14)	24 (15)	NA	NA	NA
Prior radiotherapy	34 (10)	17 (10)	NA	NA	NA

BCLC: Barcelona Clinic Liver Cancer stage; ECOG: Eastern Cooperative Oncology Group; HCC: Hepatocellular carcinoma; IC: Immune cells; IQR: Interquartile range; NA: Not available; PD-L1: Programmed death-ligand 1; TC: Tumor cells.

> Hazard ratio for deaths and PFS: According to Finn et al[12], the stratified hazard ratio (HR) for death was 0.58 (95% confidence interval [CI]: 0.42-0.79; *P* < 0.001), whereas Lee *et al*[16] did not report on HR for death but rather estimated the HR for PFS stratified HR 0.55 (80%CI: 0.40-0.74; P = 0.011) in Group F (Table 3).

Secondary outcomes

Overall/median survival: According to Finn et al[12], the estimated rates of OS at 6 and 12 mo were 84.8% (95%CI: 80.9-88.7) and 67.2% (95%CI: 61.3-73.1) in the atezolizumab/bevacizumab group, respectively. These results were significantly higher compared to 72.2% (95%CI: 65.1-79.4) and 54.6% (95%CI: 45.2-64.0) in the sorafenib group, respectively (P < 0.001) (Table 3). For Lee *et al*[16], median OS in Group A atezolizumab/bevacizumab was 17.1 mo (95%CI: 13.8 to not estimable), with only 55% (57 patients) still alive at the end of the surveillance. Median OS was not reached in atezolizumab/bevacizumab Group F. Additionally, neither Group F nor the atezolizumab group had estimable results as follows: (atezolizumab/bevacizumab: 95%CI: 8.3 mo to not estimable; atezolizumab group: 8.2 mo to not estimable).

Median PFS: Both studies reached significantly longer PFS in the atezolizumab/ bevacizumab dataset vs their respective monotherapy data set. In detail, median PFS was 6.8 mo (95%CI: 5.7-8.3) for patients treated with atezolizumab/bevacizumab compared to 4.3 mo (95%CI: 4.0-5.6] for patients treated with sorafenib alone in Finn et al[12] study (P < 0.001). On the other hand, for Lee *et al*[16], median PFS was 7.3 mo (95%CI: 5.4-9.9) and 5.6 mo (95%CI: 3.6-7.4) in Group A and Group F (atezolizumab/ bevacizumab), respectively, vs 3.4 mo (95% CI: 1.9-5.2) for atezolizumab monotherapy (*P* < 0.001) (Table 3).

Disease progression or death: At baseline, Finn et al[12] reported higher extrahepatic spread in 212/336 patients (63%) in the atezolizumab/bevacizumab group compared to 93/165 patients (56%) in the sorafenib group (P = 0.0005, by χ^2) (Table 2). These percentages were significantly lower than those observed by Lee et al[16], where extrahepatic spread was shown in 91/104 (88%), 47/50 (78%), and 50/69 (85%) patients, for Groups A, F (atezolizumab/bevacizumab), and atezolizumab monotherapy, respectively (P = 0.004 by χ^2). Moreover, in the study of Finn *et al*[12] atezolizumab/bevacizumab and sorafenib groups experienced similar disease progression (58.6% [97/336 patients] vs 66.1% [109/165 patients]; P = 0.10 by χ^2) (Table 3). The stratified HR for progression or death was estimated to be 0.58 (95%CI: 0.42-0.79; *P* < 0.001).

Tumor response rate: A better overall tumor-confirmed objective response with combination therapy compared to the respective monotherapies in the control groups



Table 3 Summary of the e	fficacy and safety findings				
Ref.	Finn e <i>t al</i> [12], 2020		Lee <i>et al</i> [<mark>16</mark>], 2020		
Schemes	Atezolizumab-bevacizumab combination therapy	Sorafenib monotherapy	Atezolizumab-bevacizumab combination therapy given in both Arm A and F		Atezolizumab monotherapy
Total patients			Group A	Group F+	
	<i>n</i> = 336	<i>n</i> = 165	n = 104	n = 60	<i>n</i> = 59
Primary efficacy outcomes					
Mortality					
n (%)	96 (28.6)	65 (39.4)	16 (27)	0 (0)	18 (31)
Two-tail <i>P</i> value	<i>P</i> = 0.0033	P = 0.0033	No <i>P</i> value reported	No <i>P</i> value reported	No <i>P</i> value reported
HR for disease progression, CI	0.59, 95%CI: 0.47-0.76	Not applicable	NA	NA	NA
ſwo-tail <i>P</i> value	P < 0.001				
HR for death, CI	0.58, 95%CI: 0.42-0.79	NA	NA	NA	NA
Гwo-tail <i>P</i> value	P < 0.001				
HR for progression-free survival, CI	NA	NA	0.55, 80%CI: 0.40-0.74		NA
Гwo-tail <i>P</i> value			P = 0.011		
Secondary efficacy outcomes tumor survival and progression of disease					
Overall/survival rate, <i>n</i> (%)	<i>n</i> not explicitly reported	<i>n</i> not explicitly reported	57 (55)	16 (27)	18 (31)
1 (%)	-67.2	-54.6			
95%CI			CI not reported	CI not reported	CI not reported
	61.3-73.1	45.2-64			
Median overall survival in mo	Not estimable	13.2 mo	17.1 mo	Median overall survival was not reached	Median overall survival was not reached
95%CI					
		(10.4 to not estimable)	(13.8 to not estimable)	(8.3 to not estimable)	(8.2 to not estimable)
6 mo overall survival rates			NA	NA	NA
95%CI	84.80%	72.20%			
	80.9-88.7	80.9-88.7			
2 mo overall survival rates	67.20%	54.60%	NA	NA	NA
95%CI	61.3-73.1	45.2-64			
Median progression-free survival (mo), (95%CI)	6.8 mo	4.3 mo	7.3 mo	5.6 mo	3.4 mo
	(5.7-8.3)	(4.0-5.6)	(5.4-9.9)	(3.6-7.4)	(1.9-5.2)
Overall confirmed objective response				<i>n</i> not explicitly reported (20%)	<i>n</i> not explicitly reported (17%)
n (%) as per RECIST 1.1				(11-32)	(8-29)
95%CI	89 (27.3%)	19 (11.9%)	37 (36%)		
	(22.5-32.5)	(7.4-18)	(26-46)		
Confirmed objective response-complete response as <i>per</i> RECIST 1.1, <i>n</i> (%)	18 (5.5)	0 (0)	12 (12)	1 (2)	3 (5)



Confirmed objective response-Partial response as <i>per</i> RECIST 1.1, <i>n</i> (%)	71 (21.8)	19 (11.9)	25 (24)	11 (18)	7 (12)
Stable disease <i>n</i> (%) as <i>per</i> RECIST 1.1	151 (46.3)	69 (43.4)	37 (36)	28 (47)	19 (32)
Progressive disease					
n (%) as per RECIST 1.1	64 (19.6)	39 (24.5)	25 (24)	17 (28)	25 (42)
Disease control rate, n (%)	240 (73.6)	88 (55.3)	74 (71)	40 (67)	29 (49)
Ongoing objective response at data cut off, n (%)	77/89 (86.5)	13/19 (68.4)	NA	NA	NA
Safety outcomes (adverse events)					
Overall patients with an adverse event from any cause, n (%)	323 (98.2)	154 (98.7)	100 (96)	57 (95)	52 (90)
Treatment-related serious adverse events, n (%)	125 (38)	48 (30.8)	25 (24)	7 (12)	2 (3)
Treatment-related mortality	161 deaths (%)		3 (3%)	0 (%)	NA
	It was not explicitly stated how many deaths there were in relation to treatment in either intervention or control arm ¹				
Adverse events leading to dose modifications, n (%)	163 (49.5)	95 (60.9)	50 (48)	9 (15)	5 (9)
Adverse events leading to withdrawal from any trial drug, n (%)	51 (15.5)	16 (10.3)	18 (17)	6 (10)	0 (0)
Number of participants with Grade 3 and above, <i>n</i> (%)	5-15 (4.6)	9 (5.8)	55 (53)	22 (37)	8 (14)
Types of Grade 3-4 adverse events					
Adverse events	Note: All stratified data reporte Grade 3 or 4	ed below are	Note: All stratified data reported below are Grade 3, except increased aspartate aminotransferase (note stratification)		
Hypertension, <i>n</i> (%)			stratification		
Decreased appetite, n (%)	50 (15.2)	19 (12.2)	15 (14)	3 (5)	1 (1)
Decreased appende, n (%)	50 (15.2) 4 (1.2)	19 (12.2) 6 (3.8)	,	3 (5) 0 (0)	1 (1) 0 (0)
Fatigue, <i>n</i> (%)		. ,	15 (14)		
	4 (1.2)	6 (3.8)	15 (14) 1 (1)	0 (0)	0 (0)
Fatigue, n (%)	4 (1.2) 8 (2.4)	6 (3.8) 5 (3.2)	15 (14) 1 (1) 1 (1)	0 (0) 0 (0)	0 (0) 0 (0)
Fatigue, <i>n</i> (%) Pyrexia, <i>n</i> (%)	4 (1.2) 8 (2.4) 4 (1.2)	6 (3.8) 5 (3.2) 2 (1.3)	15 (14) 1 (1) 1 (1) 2 (2)	0 (0) 0 (0) 0 (0)	0 (0) 0 (0) 0 (0)
Fatigue, <i>n</i> (%) Pyrexia, <i>n</i> (%) Rash, <i>n</i> (%)	4 (1.2) 8 (2.4) 4 (1.2) 0 (0)	6 (3.8) 5 (3.2) 2 (1.3) 4 (2.6)	15 (14) 1 (1) 1 (1) 2 (2) 0 (0)	0 (0) 0 (0) 0 (0) 0 (0)	0 (0) 0 (0) 0 (0) 0 (0)
Fatigue, <i>n</i> (%) Pyrexia, <i>n</i> (%) Rash, <i>n</i> (%) Diarrhea, <i>n</i> (%)	4 (1.2) 8 (2.4) 4 (1.2) 0 (0) 6 (1.8)	6 (3.8) 5 (3.2) 2 (1.3) 4 (2.6) 8 (5.1)	15 (14) 1 (1) 1 (1) 2 (2) 0 (0) 3 (3)	0 (0) 0 (0) 0 (0) 0 (0) 1 (2)	0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Fatigue, <i>n</i> (%) Pyrexia, <i>n</i> (%) Rash, <i>n</i> (%) Diarrhea, <i>n</i> (%) Abdominal pain, <i>n</i> (%)	4 (1.2) 8 (2.4) 4 (1.2) 0 (0) 6 (1.8) 4 (1.2)	6 (3.8) 5 (3.2) 2 (1.3) 4 (2.6) 8 (5.1) 4 (2.6)	15 (14) 1 (1) 1 (1) 2 (2) 0 (0) 3 (3) 4 (4)	0 (0) 0 (0) 0 (0) 0 (0) 1 (2) 0 (0)	0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Fatigue, <i>n</i> (%) Pyrexia, <i>n</i> (%) Rash, <i>n</i> (%) Diarrhea, <i>n</i> (%) Abdominal pain, <i>n</i> (%) Constipation, <i>n</i> (%)	4 (1.2) 8 (2.4) 4 (1.2) 0 (0) 6 (1.8) 4 (1.2) 0 (0)	6 (3.8) 5 (3.2) 2 (1.3) 4 (2.6) 8 (5.1) 4 (2.6) 0 (0)	15 (14) 1 (1) 1 (1) 2 (2) 0 (0) 3 (3) 4 (4) 1 (1)	0 (0) 0 (0) 0 (0) 0 (0) 1 (2) 0 (0) 0 (0)	0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Fatigue, <i>n</i> (%) Pyrexia, <i>n</i> (%) Rash, <i>n</i> (%) Diarrhea, <i>n</i> (%) Abdominal pain, <i>n</i> (%) Constipation, <i>n</i> (%) Cough, <i>n</i> (%)	4 (1.2) 8 (2.4) 4 (1.2) 0 (0) 6 (1.8) 4 (1.2) 0 (0) 0 (0)	6 (3.8) 5 (3.2) 2 (1.3) 4 (2.6) 8 (5.1) 4 (2.6) 0 (0) 1 (0.6)	15 (14) 1 (1) 1 (1) 2 (2) 0 (0) 3 (3) 4 (4) 1 (1) 0 (0)	0 (0) 0 (0) 0 (0) 1 (2) 0 (0) 0 (0) 0 (0)	0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Fatigue, <i>n</i> (%) Pyrexia, <i>n</i> (%) Rash, <i>n</i> (%) Diarrhea, <i>n</i> (%) Abdominal pain, <i>n</i> (%) Constipation, <i>n</i> (%) Cough, <i>n</i> (%) Nausea, <i>n</i> (%)	4 (1.2) 8 (2.4) 4 (1.2) 0 (0) 6 (1.8) 4 (1.2) 0 (0) 0 (0) 1 (0.3)	6 (3.8) 5 (3.2) 2 (1.3) 4 (2.6) 8 (5.1) 4 (2.6) 0 (0) 1 (0.6) 1 (0.6)	15 (14) 1 (1) 1 (1) 2 (2) 0 (0) 3 (3) 4 (4) 1 (1) 0 (0) NA	0 (0) 0 (0) 0 (0) 1 (2) 0 (0) 0 (0) 0 (0) NA	0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) NA
Fatigue, n (%) Pyrexia, n (%) Rash, n (%) Diarrhea, n (%) Abdominal pain, n (%) Constipation, n (%) Cough, n (%) Nausea, n (%) Weight decrease, n (%)	4 (1.2) 8 (2.4) 4 (1.2) 0 (0) 6 (1.8) 4 (1.2) 0 (0) 0 (0) 1 (0.3) 0 (0)	6 (3.8) 5 (3.2) 2 (1.3) 4 (2.6) 8 (5.1) 4 (2.6) 0 (0) 1 (0.6) 1 (0.6) 1 (0.6)	15 (14) 1 (1) 2 (2) 0 (0) 3 (3) 4 (4) 1 (1) 0 (0) NA NA	0 (0) 0 (0) 0 (0) 1 (2) 0 (0) 0 (0) 0 (0) NA NA	0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) NA NA
Fatigue, <i>n</i> (%) Pyrexia, <i>n</i> (%) Rash, <i>n</i> (%) Diarrhea, <i>n</i> (%) Abdominal pain, <i>n</i> (%) Constipation, <i>n</i> (%) Cough, <i>n</i> (%) Nausea, <i>n</i> (%) Weight decrease, <i>n</i> (%) Epistaxis, <i>n</i> (%)	4 (1.2) 8 (2.4) 4 (1.2) 0 (0) 6 (1.8) 4 (1.2) 0 (0) 0 (0) 1 (0.3) 0 (0) 0 (0)	6 (3.8) 5 (3.2) 2 (1.3) 4 (2.6) 8 (5.1) 4 (2.6) 0 (0) 1 (0.6) 1 (0.6) 1 (0.6) 1 (0.6)	15 (14) 1 (1) 2 (2) 0 (0) 3 (3) 4 (4) 1 (1) 0 (0) NA NA NA	0 (0) 0 (0) 0 (0) 1 (2) 0 (0) 0 (0) 0 (0) NA NA NA	0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) NA NA NA
Fatigue, n (%) Pyrexia, n (%) Rash, n (%) Diarrhea, n (%) Abdominal pain, n (%) Constipation, n (%) Cough, n (%) Nausea, n (%) Weight decrease, n (%) Epistaxis, n (%) Asthenia, n (%) Infusion-related reaction, n	4 (1.2) 8 (2.4) 4 (1.2) 0 (0) 6 (1.8) 4 (1.2) 0 (0) 0 (0) 1 (0.3) 0 (0) 1 (0.3)	6 (3.8) 5 (3.2) 2 (1.3) 4 (2.6) 8 (5.1) 4 (2.6) 0 (0) 1 (0.6) 1 (0.6) 1 (0.6) 1 (0.6) 4 (2.6)	15 (14) 1 (1) 2 (2) 0 (0) 3 (3) 4 (4) 1 (1) 0 (0) NA NA NA NA	0 (0) 0 (0) 0 (0) 1 (2) 0 (0) 0 (0) 0 (0) NA NA NA	0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) NA NA NA NA



Ahmed F et al. Efficacy and safety of atezolizumab with bevacizumab

erythrodysesthesia syndrome, <i>n</i> (%)					
Proteinuria, n (%)	10 (3)	1 (0.6)	7 (7)	3 (5)	0 (0)
Increased aspartate	23 (7.0)	8 (5.1)	Grade 3: 3 (3)	2 (3)	2 (3)
aminotransferase, n (%)			Grade 4: 2 (2)		
Increased alanine aminotransferase, <i>n</i> (%)	12 (3.6)	2 (1.3)	NA	NA	NA
Blood bilirubin increase, <i>n</i> (%)	8 (2.4)	10 (6.4)	NA	NA	NA
Decreased platelet count, <i>n</i> (%)	11 (3.3)	2 (1.3)	5 (5)	0 (0)	0 (0)
Pancreatitis, n (%)	1 (0.3)	2 (1.3)	NA	NA	NA
Hepatic Encephalopathy, <i>n</i> (%)	2 (0.6)	2 (1.3)	NA	NA	NA
Pulmonary Embolism, <i>n</i> (%)	3 (0.9)	2 (1.3)	NA	NA	NA
Cholangitis, n (%)	4 (1.2)	1 (0.6)	NA	NA	NA
Acute kidney failure, n (%)	1 (0.3)	3 (1.9)	NA	NA	NA
Gastrointestinal hemorrhage, <i>n</i> (%)	4 (1.2)	3 (1.9)	NA	NA	NA
Esophageal varices hemorrhage, <i>n</i> (%)	6 (1.8)	1 (0.6)	NA	NA	NA
Upper gastrointestinal hemorrhage, n (%)	2 (0.6)	2 (1.3)	NA	NA	NA
Asthenia, n (%)	1 (0.3)	4 (2.6)	NA	NA	NA
Types of Grade 5 adverse events					
Grade 5 adverse events, <i>n</i> (%)	15 (4.6)	9 (5.8)	0 (0)	0 (0)	0 (0)
	Not stratified ¹	Not stratified ¹			
Not evaluable/data missing					
Not evaluable, n (%)	8 (2.5)	14 (8.8)	NA	NA	NA
Data missing, <i>n</i> (%)	14 (4.3)	18 (11.3)	NA	NA	NA

¹Group A: Patients with hepatitis B virus DNA of 500 IU/mL or less and ongoing anti-hepatitis B virus treatment for at least 3 mo before and at study entry. Patients enrolled in group F must have had hepatitis B virus DNA of 500 IU/mL or less measured up to 28 d before study entry and anti-hepatitis B virus treatment for at least 14 d before study entry. +: Group F: Patients in Child-Pugh class A, life expectancy of 3 mo and platelet count or > 75000/µL; CI: Confidence interval; HR: Hazard ratio; NA: Not available.

was reported. For Finn *et al*[12], a significantly higher overall tumor response was observed in 89/336 patients (27.3%; 95%CI: 22.5-32.5) with atezolizumab/ bevacizumab combination therapy than the one obtained with sorafenib in 19/165 patients (11.9%; 95%CI: 7.4-18.0) (P < 0.001 by χ^2). Whereas Lee *et al*[16] detected a better overall tumor response in Group A of the combination therapy compared to Group F and the atezolizumab group, which were similar (36% [95%CI: 26-46] *vs* 20% [95%CI: 11-32] *vs* 17% [95%CI: 8-29]; P = 0.011). Further details concerning the other indices of tumor response, including the confirmed partial/complete/ongoing objective responses are shown in Table 3.

Disease control rate: The disease control rate was significantly higher in both trials for atezolizumab/bevacizumab combination therapy than sorafenib or atezolizumab monotherapies (Table 3). The estimates were 73.6% (240/336 patients) *vs* 55.3% (88/165 patients) for atezolizumab/bevacizumab and sorafenib (P < 0.001 by χ^2), and 71% (74/104 patients), 67% (40/60 patients), and 49% (29/58 patients) for Group A, Group F and atezolizumab (P = 0.016 by χ^2), respectively.

Zaishidena® WJGO | https://www.wjgnet.com

Safety outcomes and AEs

Overall AEs: Finn *et al*[12] estimated similar AEs that were contributed from any cause in 98.2% (323/336 patients) and 98.7% (154/165 patients) for the atezolizumab/ bevacizumab *vs* sorafenib monotherapy groups (P = 0.17 by χ^2), respectively. Likewise, according to Lee *et al*[16], 96% (100/104 patients), 95% (57/60 patients), and 90% (52/58 patients) for Groups A/F (atezolizumab/bevacizumab) and atezolizumab (P = 0.13 by χ^2), respectively (Table 3).

Treatment-related serious AEs: Finn *et al*[12] reported higher treatment-related AEs with atezolizumab/bevacizumab compared to sorafenib monotherapy (38% [125/336 patients] *vs* 30.8% [48/165 patients]; *P* < 0.0001 by χ^2). Lee *et al*[16] recorded 24% (25/104 patients), 12% (7/60 patients), and 3% (2/58 patients) for Groups A/F (atezolizumab/bevacizumab) and atezolizumab (*P* < 0.001 by Fisher's Exact Test), respectively (Table 3).

Grade 3-5 AEs: Details of the treatment-related deaths and severe AEs as well as other indices of safety are shown in Table 3. Finn *et al*[12] and Lee *et al*[16] reported Grade 3-5 AEs in 10% and 15% of participants, respectively. In the Finn *et al*[12] study, hypertension occurred in 15.2% and 12.2% for the combination therapy and sorafenib monotherapy groups, and 14%, 5%, and 1% in Groups A/F (atezolizumab/ bevacizumab) and atezolizumab, respectively (Lee *et al*[16]). Furthermore, Proteinuria occurred in 3% and 0.6% in the combination therapy and sorafenib monotherapy groups, respectively, whereas in 7%, 5%, and 0% for Groups A/F (atezolizumab/ bevacizumab) and atezolizumab groups, respectively. Other Grade 3-5 AEs that were reported included abdominal pain, fatigue, rashes, pyrexia, and palmar-plantar erythrodysesthesia syndrome (Table 3). Finn *et al*[12] registered fewer Grade 5 AEs in the combination therapy (4.6% *vs* 5.8%), whereas Lee *et al*[16] study registered 0% of such events.

RoB of included studies

The RoB assessment for Finn *et al*[12] and Lee *et al*[16] trials resulted in high quality with a low RoB. However, in the two ongoing studies (La Roche[14] and Hack *et al*[15]), the RoB was not evaluated given that incomplete information existed (Figures 1 and 2).

Randomization and allocation concealment

Both completed trials (Finn *et al*[12] and Lee *et al*[16]) showed adequate randomization with a low RoB arising from the randomization process that was performed through an interactive voice-response or Web-response system in permuted blocks. There was also fair allocation concealment. For Lee *et al*[16], an independent statistician was responsible for generating the randomization sequence, which was subsequently stored within the interactive voice systems.

Blinding and bias arising from deviations from intended interventions

In both completed studies (Finn *et al*[12] and Lee *et al*[16]), open-label trials were implemented, and consequently had neither blinding nor masking of interventions. Lee *et al*[16] described 26 participants who deviated from the initially assigned atezol-izumab/bevacizumab to atezolizumab monotherapy without describing post-crossover efficacy and safety results. Moreover, Finn *et al*[12] found it less cumbersome to not administer intravenous placebo infusions. Hence, due to the lack of blinding or masking and because of deviations from intended interventions, the two completed studies were estimated to have some RoB concerns.

Bias arising from incomplete or missing outcome data, measurement of the outcome, and selection of the reported results

All RCT results showed a low risk of attrition bias from the missing outcome data. Both studies also had appropriate measurements of survival outcomes (Finn *et al*[12]). For example, both used PFS and objective tumor response with the RECIST 1.1 (Supplementary Table 1) as well as the HCC-specific mRECIST by investigator assessment and independent faculty review. Thus, they displayed a low risk of measurement bias as well as lower selective reporting bias.

DISCUSSION

In the past, early-stage HCC has been treated with surgical treatment and/or thermal ablation. These procedures have been associated with high recurrence rates and therefore considered to have poor prognosis. The development of immunotherapy has led to new alternatives in treating HCC patients with advanced stages of the disease, who are considered unresectable with the standard surgery. Different treatments have been used for unresectable cases of HCC, including ICIs and VEGF inhibitors such as sorafenib, atezolizumab, and bevacizumab (Supplementary Figure 2).

In this systematic review, the results of Finn *et al*[12] and Lee *et al*[16] studies were summarized. The purpose was to combine with their studies the ongoing results of the two additional trials of La Roche^[14] and Hack *et al*^[15] to determine which of the therapeutic regimens could support a stellar efficacy and safety profile. Two clinical trials included 724 participants in about 137 sites in over 19 different countries were identified (Figure 4). The completed trials of Finn *et al*[12] and Lee *et al*[16] recruited participants mostly from the United States, Canada, the United Kingdom, Germany, France, Italy, Poland, Spain, Russia, Czech Republic, China mainland, Japan, Republic of South Korea, Taiwan, Australia, Hong Kong, Russia, Singapore, and New Zealand, which are mostly high and middle-income countries[17]. Both trials were assessed as having an overall low RoB outcome.

The results of this review demonstrate that the combination of atezolizumab/ bevacizumab had a beneficial effect on improving the overall efficacy and safety in treating patients with early-stage HCC compared to sorafenib or atezolizumab monotherapy. The combination therapy resulted in the prevention of mortality, increased OS and PFS rates, as well as better disease control and response rate. However, the proportion of participants with AEs from any cause were similar in both trials (Table 3).

Specifically, Finn et al[12] showed a higher OS rate with atezolizumab/bevacizumab than sorafenib groups along with a 42% reduced hazard of death at 6 and 12 mo of surveillance[12]. PFS rate and time were significantly higher in the atezolizumab/ bevacizumab group when compared to sorafenib (54.5% vs 37.2% and 6.8 mo vs 4.3 mo, respectively)[12]. Finn et al[12] reported a significantly lower mortality rate in the atezolizumab/bevacizumab than the sorafenib group at a median follow-up of 8.6 mo (28.6% vs 39.4%). The overall confirmed objective response, disease control rate, and median time to deterioration of quality of life were better in the atezolizumab/ bevacizumab group compared to the sorafenib group[12]. The objective response in the Finn et al[12] and Lee et al[16] studies were more than two times higher using the combination therapy than the monotherapy (27.3% vs 11.9% and 36% vs 17%, respectively).

In the Lee *et al*[16] study, the atezolizumab/bevacizumab combination was given in both Groups A and F as specified in the study protocol. Median OS was estimated to be 17.1 mo in the atezolizumab/bevacizumab group but was not estimated for the atezolizumab monotherapy group. In both Groups A and F, objective response was confirmed with the primary endpoint according to RECIST 1.1. Secondary efficacy outcomes were also achieved that included objective response (based on RECIST 1.1 assessment) and independent review assessment (HCC specific mRECIST) showing PFS, duration of response, and time to radiographic progression. Irrespective of PD-L1 status, there was a progressive survival benefit with atezolizumab/bevacizumab compared to the atezolizumab monotherapy. This progressive survival benefit was observed despite the difficulty experienced comparing efficacy within Groups A and F due to the varied follow-up periods[16]. Moreover, Lee et al[16] reported that responses with long surveillance were expected to change in Group F. Lee et al[16] also recorded a 27% and 0% mortality in the combination therapy Groups A and F, which was significantly lower compared to the 31% in the monotherapy group at the median 12.4 mo follow-up duration. The overall response rate was statistically significant in the combination therapy group (atezolizumab/bevacizumab) compared to the monotherapy group, especially with sorafenib[16]. Thus, in this study[16] the primary endpoint was PFS as per RECIST 1.1 and OS. IMbrave 150 results demonstrated a significantly better PFS, OS, and response rate with atezolizumab/bevacizumab combination therapy than with sorafenib[18].

Ongoing trials by La Roche^[14] and Hack *et al*^[15] are phase III randomized trials with atezolizumab/bevacizumab. Although the trials have not yet been finalized, the results to date are considered meaningful and support the objective of their study. In Finn *et al*[12], and Lee *et al*[16] studies, the profile of safety outcomes were rather comparable with the exception concerning the AEs related to dose modifications which were lower in the combination (atezolizumab/bevacizumab) therapy group



than monotherapy (sorafenib) group (Finn et al[12]). Moreover, Finn et al[12] also showed a slightly higher rate of AEs with Grade 3 and above, especially regarding objective response in the atezolizumab/bevacizumab group compared to the sorafenib group (86.5% vs 68.4%, respectively). The rate of AEs leading to withdrawal from any drug trials in the atezolizumab/bevacizumab therapy group was significantly greater compared to the sorafenib group (15.5% vs 10.3%, respectively). The rate of AEs more than Grade 3 was less in the atezolizumab/bevacizumab group than the sorafenib group (4.6% vs 5.8%, respectively).

Overall, combination therapy demonstrated a better safety profile in both studies. There was a difference in the types of Grade 3-5 AEs reported in Finn et al [12] such as palmar-plantar erythrodysesthesia syndrome and increased bilirubin as well as infusion-related reactions, which were not reported in the study by Lee *et al*[16]. In Finn *et al*[12], hypertension occurred at a slightly higher rate in the atezolizumab/ bevacizumab group than in the sorafenib monotherapy group (15% vs 12%, respectively). Infusion-related reaction only occurred in the atezolizumab/ bevacizumab group (2.4% of cases) and additionally, palmar-plantar erythrodysesthesia syndrome was detected in the sorafenib group (8.3%). Furthermore, the occurrence of abdominal pain and asthenia was low in the atezolizumab/bevacizumab group (1.2% and 0.3%, respectively) compared to the sorafenib group (2.6% and 2.6%, respectively). There was also a mild increase in proteinuria (3%), aspartate aminotransferase (7%), alanine aminotransferase (3.6%) in those treated with atezolizumab/ bevacizumab combination therapy compared to those treated with sorafenib alone (proteinuria [0.6%], aspartate aminotransferase [5.1%], alanine aminotransferase [1.3%]). There was also a slight decrease in platelet count in the atezolizumab/ bevacizumab group (3.3%) compared to sorafenib monotherapy (1.3%)[12].

In Lee et al[16], AEs leading to withdrawal from the trial were reported only in Groups A and F (17% and 10%, respectively). The rate of AEs Grade 3 and above was greater in combination therapy (53% for Group A and 37% for Group F) than atezolizumab monotherapy (14%). Some differences in the Grade 3-5 types of AEs especially were identified with Group A when compared to atezolizumab alone. For instance, when considering the prevalence of hypertension as one of the most commonly occurring AEs, it was present in 14% of Group A and 5% of patients in Group F. Thus, these figures were slightly higher than the atezolizumab group (1%). Additionally, fatigue, abdominal pain, and asthenia occurred only in 1% and 4% of patients in Group A, when compared to Group F or atezolizumab monotherapy. Proteinuria in combination therapy was similar in Groups A and F (7% vs 5%)[16].

A major limitation of this review was that supportive evidence was based on a limited number of completed clinical trials used in the treatment of HCC. Moreover, there was inadequate applicability in low-income countries or developing countries where these novel immune therapies may not be available. Despite the limitations, the analysis of the studies reviewed in this document was considered overall satisfactory.

Additional study limitations included that both Lee *et al*[16] and Finn *et al*[12] studies were open-label trials that held a higher risk for bias. Although independent faculty reviewers were used to reduce the potential biases, there were no blinding or masking of the investigators and participants, thus further sustaining the potential for bias. In Lee et al[16], it was challenging to compare the efficacy among Groups A and F due to their different follow-up periods. Also, Lee et al[16] reported crossover participants from monotherapy to combination therapy; however, post-crossover results were not mentioned. The aforementioned could have further created some kind of reporting bias, decreasing the quality of the study. Although both RCTs were satisfactory in terms of quality, they did not present robust evidence. Additionally, indepth cost-effectiveness analysis, which could have provided further support, was not performed.

It is of great importance to consider cost-effectiveness for combination therapies to be effectively administered worldwide. A study (Hou and Wu[19], 2020) conducted in China, stated that in the base-case analysis, atezolizumab/bevacizumab gained a marginal 0.811 quality-adjusted life-year (QALY) and 1.297 overall life-years with an augmented cost of \$49994 as compared with sorafenib, which led to an incremental cost-effectiveness ratio (ICER) of \$61613/QALY[16]. The study by Wang et al[20] (2021), conducted using the IMIbrave 150 trial evaluation, reported that atezolizumab/bevacizumab treatment resulted in an increase of 0.623 Life-years, 0.484 QALYs, and \$158781 per patient at the base case analysis^[20]. The ICER was \$322500 per QALY (95%CI: 136275-801509 per QALY)[20]. The negative incremental net benefit of -0.810 QALY reported by Hou et al[19] (2020) as well as the ICER of \$322500 per QALY reported by Wang et al^[20] (2021) was considered to be rather expensive for combination therapy implementation.



Conversely, both completed trials[12,16] demonstrated promising results in terms of better combination therapy efficacy with atezolizumab/bevacizumab compared to monotherapy (either sorafenib or atezolizumab). PD-1 and PD-L1 play key roles by escaping tumor immune surveillance in tumor progression and survival[15,21]. The PD-1 and PD-L1 antibody inhibitors act against PD-1 or PD-L1, and stimulate T-cell mediated immunity. Although PD-1 is mostly expressed on T cells, they also activate PD-L1 on cancer cells and antigen-presenting cells [15,21]. Therefore, PD-L1 inhibitors cause the resurrection of T-cell mediated anti-tumor immune effects unless other T-cell regulatory proteins are blocked such as cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), thus resulting in improved cancer immunotherapy[15,21].

The CTLA-4 antibody inhibitor (ipilimumab) and PD-1 inhibitors (pembrolizumab, nivolumab) have both been approved for treating various solid tumors including lung cancer, renal cell cancer, and ovarian cancer. Other anti-tumor agents such as kinase inhibitors, checkpoint inhibitors, and targeting agents are used in combination with PD-1 antibody inhibitors[11,22,23]. Even though clinical data show monotherapy as a successful immunotherapy regimen when focusing on safety and efficacy the clinical data shows that novel combination therapies are superior to monotherapy[7].

CONCLUSION

In this review, findings confirm that atezolizumab/bevacizumab combination therapy can be an effective first-line treatment option to either sorafenib or atezolizumab monotherapy in patients with advanced HCC and non-decompensated liver disease. However, due to the small number of RCTs included, this systematic review may be considered insufficiently robust to provide strong recommendations. Consequently, further research and larger RCTs with cost-effectiveness analysis are necessary to validate our observations and identify the most efficacious and safe therapeutic regimen.

ARTICLE HIGHLIGHTS

Research background

Despite the use of the current standard therapy, the prognosis of unresectable hepatocellular carcinoma (HCC) patients is poor, with median survival times of 40 mo in intermediate HCC (Barcelona Clinic Liver Cancer [BCLC] stage B) and 6-8 mo in advanced HCC (BCLC stage C). Although patients with early-stage HCC are usually suitable for therapies with curative intention, up to 70% of patients may manifest disease relapses at 5-year surveillance. Moreover, no treatment has been demonstrated to be useful in the adjuvant setting.

Research motivation

This systematic review described the evidence for atezolizumab/bevacizumab combination therapy vs sorafenib or atezolizumab monotherapies in improving survival outcomes and reducing disease progression in patients with unresectable HCC.

Research objectives

To evaluate the efficacy and safety of atezolizumab/bevacizumab vs sorafenib or atezolizumab alone, in patients with unresectable HCC with non-decompensated liver disease.

Research methods

A comprehensive literature review of published articles was conducted to identify studies that met our inclusion criteria using relevant mesh terms. This systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and we assessed for risk of bias using the Cochrane ROB tool and Sevis tool to create the traffic light plots and summary plots.

Research results

There was an improvement in overall tumor response, reduction of disease progression, and longer progression-free survival in the atezolizumab/bevacizumab



group compared to the monotherapy of either sorafenib or atezolizumab.

Research conclusions

This study confirms that combination treatment of atezolizumab plus bevacizumab could be a promising alternative to the standard of care sorafenib as a first-line treatment in patients with unresectable HCC and non-decompensated liver disease.

Research perspectives

Given the scarcity of randomized controlled trials specifically focusing on this therapeutic strategy, further research is needed to strengthen the current evidence. Two completed clinical trials were analyzed in this research; however, this review will be updated upon the completion of two ongoing trials. Moreover, further evaluation regarding the cost-effectiveness of combination therapy vs monotherapy is still needed valuable information.

ACKNOWLEDGEMENTS

We sincerely acknowledge Dr. Karthik Mohan, MD and Dr. Jack Michel, MD for their guidance and support throughout the completion of this project.

REFERENCES

- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: 1 GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424 [PMID: 30207593 DOI: 10.3322/caac.21492]
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018; 69: 182-236 [PMID: 29628281 DOI: 10.1016/j.jhep.2018.03.019]
- Brown ZJ, Greten TF, Heinrich B. Adjuvant Treatment of Hepatocellular Carcinoma: Prospect of 3 Immunotherapy. Hepatology 2019; 70: 1437-1442 [PMID: 30927283 DOI: 10.1002/hep.30633]
- Liu X, Qin S. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges. Oncologist 2019; 24: S3-S10 [PMID: 30819826 DOI: 10.1634/theoncologist.2019-IO-S1-s01]
- Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-7109 [PMID: 15466206 DOI: 10.1158/0008-5472.CAN-04-1443]
- Ranieri G, Gadaleta-Caldarola G, Goffredo V, Patruno R, Mangia A, Rizzo A, Sciorsci RL, Gadaleta 6 CD. Sorafenib (BAY 43-9006) in hepatocellular carcinoma patients: from discovery to clinical development. Curr Med Chem 2012; 19: 938-944 [PMID: 22214462 DOI: 10.2174/092986712799320736
- Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK, Iyer AK. PD-1 and PD-L1 7 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome. Front Pharmacol 2017; 8: 561 [PMID: 28878676 DOI: 10.3389/fphar.2017.00561]
- Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515: 563-567 [PMID: 25428504 DOI: 10.1038/nature14011]
- 9 Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005; 333: 328-335 [PMID: 15961063 DOI: 10.1016/j.bbrc.2005.05.132]
- 10 Wallin JJ, Bendell JC, Funke R, Sznol M, Korski K, Jones S, Hernandez G, Mier J, He X, Hodi FS, Denker M, Leveque V, Cañamero M, Babitski G, Koeppen H, Ziai J, Sharma N, Gaire F, Chen DS, Waterkamp D, Hegde PS, McDermott DF. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat Commun 2016; 7: 12624 [PMID: 27571927 DOI: 10.1038/ncomms12624]
- 11 Hegde PS, Wallin JJ, Mancao C. Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics. Semin Cancer Biol 2018; 52: 117-124 [PMID: 29229461 DOI: 10.1016/j.semcancer.2017.12.002]
- Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, 12 Li D, Verret W, Xu DZ, Hernandez S, Liu J, Huang C, Mulla S, Wang Y, Lim HY, Zhu AX, Cheng



AL; IMbrave150 Investigators. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 2020; 382: 1894-1905 [PMID: 32402160 DOI: 10.1056/NEJMoa1915745]

- 13 Casak SJ, Donoghue M, Fashoyin-Aje L, Jiang X, Rodriguez L, Shen YL, Xu Y, Liu J, Zhao H, Pierce WF, Mehta S, Goldberg KB, Theoret MR, Kluetz PG, Pazdur R, Lemery SJ. FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma. Clin Cancer Res 2021; 27: 1836-1841 [PMID: 33139264 DOI: 10.1158/1078-0432.CCR-20-3407]
- La Roche H. A Phase IIIB, Single Arm, Multicenter Study of Atezolizumab (Tecentriq) in 14 Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista. 2020. [cited 5 March 2021]. Available from: https://clinicaltrials.gov/ct2/show/NCT04487067
- 15 Hack SP, Spahn J, Chen M, Cheng AL, Kaseb A, Kudo M, Lee HC, Yopp A, Chow P, Qin S. IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. Future Oncol 2020; 16: 975-989 [PMID: 32352320 DOI: 10.2217/fon-2020-0162]
- 16 Lee MS, Ryoo BY, Hsu CH, Numata K, Stein S, Verret W, Hack SP, Spahn J, Liu B, Abdullah H, Wang Y, He AR, Lee KH; GO30140 investigators. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncol 2020; 21: 808-820 [PMID: 32502443 DOI: 10.1016/S1470-2045(20)30156-X]
- World Economic Situation and Prospects, 2018. United Nations. [cited 5 March 2021]. Available 17 from: https://www.un.org/development/desa/dpad/wpcontent/uploads/sites/45/WESP2020_Annex.pdf
- 18 Cheng AL, Qin S, Ikeda M, Galle P, Ducreux M, Zhu A, Kim TY, Kudo M, Breder V, Merle P. IMbrave150: efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC). Ann Oncol 2019; 30: ix186 [DOI: 10.1093/annonc/mdz446.002]
- 19 Hou Y. Wu B. Atezolizumab plus bevacizumab vs sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a cost-effectiveness analysis. Cancer Commun (Lond) 2020; 40: 743-745 [PMID: 33159490 DOI: 10.1002/cac2.12110]
- 20 Wang W, Wang J, Zhang X, Wang Y, Shi J, Jia X, Dang S. Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma: A cost-effectiveness analysis. J Clin Oncol 2021; **39**: 295-295 [DOI: 10.1200/JCO.2021.39.3_suppl.295]
- Callahan MK, Postow MA, Wolchok JD. CTLA-4 and PD-1 Pathway Blockade: Combinations in 21 the Clinic. Front Oncol 2014; 4: 385 [PMID: 25642417 DOI: 10.3389/fonc.2014.00385]
- 22 Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-264 [PMID: 22437870 DOI: 10.1038/nrc3239]
- 23 Chen DS, Hurwitz H. Combinations of Bevacizumab With Cancer Immunotherapy. Cancer J 2018; 24: 193-204 [PMID: 30119083 DOI: 10.1097/PPO.00000000000327]





Published by Baishideng Publishing Group Inc 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA Telephone: +1-925-3991568 E-mail: bpgoffice@wjgnet.com Help Desk: https://www.f6publishing.com/helpdesk https://www.wjgnet.com

